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Despite the development of effective vaccines, influenza still remains as a global 
concern. For appropriate public health intervention, it is crucial to accurately 
determine the routes of transmission. Influenza is believed to have three primary 
modes of transmission: big droplet, direct contact and aerosol particles. Considerable 
evidence points to both aerosol and droplet transmission routes as being significant. 
Because of the limitation of sampling and analysis, the quantitative dynamics of the 
aerosol mode of transmission are not completely understood. In this dissertation I 
have characterized the physical and biological collection efficiency of a novel 
exhaled breath aerosol collector named Gesundheit II (G-II). The device was proven 
to successfully collect and preserve infectivity with different types of influenza virus. 
I have also been involved in epidemiological data analysis, experimental 
quantification and numerical modeling. On experimental quantification, I have been 
  
part of a multi-member team that has conducted a study of characterization of 
respiratory droplets from influenza infected individuals at the University of Maryland 
campus during the flu seasons of 2012-2013. The exhaled breath was collected with 
the G-II for accurate quantification of the influenza virus. 218 pairs of fine (< 5 µm) 
and coarse (≥ 5µm) exhaled breath samples were obtained from 142 subjects and 
analyzed. The relationship between culturability, coughing frequency, and symptoms 
were investigated. The high rate of RNA detection and the frequent recovery of 
influenza virus by culture from fine aerosol samples suggest a contribution of fine 
particle aerosols in the transmission of influenza. Given these new findings, to 
understand the risk of influenza infection from these finer droplets, we have modified 
an existing mathematical risk analysis model and studied the effect of these droplets 
on subjects in presence or absence of a respiratory protective device (RPD). Two of 
the major enhancements in our model are (1) the ability to account for subject-to-
subject variability over a wide range of age groups and (2) the heterogeneous 
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CHAPTER 1: INTRODUCTION AND OVERVIEW 
This dissertation is focused on the study of the airborne transmission of influenza 
virus, and the development of a mathematical modeling approach to predict airborne 
transmission in scenarios involving use of respiratory protection devices (RPDs). In 
this chapter, I will address the overall problems and research approaches.  
1.1 Problem Description and Motivation 
Human influenza is an acute respiratory disease and is considered as one of the 
most important infectious diseases of mankind. The World Health Organization 
(WHO) estimated that annual epidemics account for an estimated three to five million 
severe illnesses and up to 500,000 deaths worldwide (Brankston et al., 2007; Elovainio, 
2008). The infection mainly occurred in the epithelial cells of the upper and lower 
respiratory tract. An accurately defined route of transmission is important for public 
health policy and practice (Atkinson and Wein, 2008; Cowling, 2012). Transmission 
of bioaerosols resulting in the spread of disease can take place via various routes. The 
modes of transmission have been well documented in the literature, but the relative 
importance of these modes has been debated in recent years. Influenza is believed to 
have three main modes of transmission: (1) by direct contact with secretions (2) by 
transport of large droplets, >5 µm in diameter, that land in the mouths, eyes, and noses 
of people nearby and (3) by aerosol transmission, breathing in smaller droplets 
suspended in the air (Weber and Stilianakis, 2008). Literature work supported that 





different sizes containing infectious virus. No strong evidence has been shown for the 
importance of simple tidal breathing in airborne transmission.  
At present, the available literature is insufficiently clear to determine which of 
these three routes of transmission plays a role in the human-human spread of influenza 
(probably all three are possible), nor the relative importance of each. Because of the 
limitation of sampling and analysis, the quantitative dynamics of the aerosol mode of 
transmission are not completely understood. Clear guidance on the prevention of 
influenza transmission in homes, schools, workplaces and healthcare settings cannot 
easily be provided while the evidence base remains unclear. For example, if 
transmission via droplet nuclei (aerosols) was shown to predominate, control measures 
in healthcare settings might include ventilation and ultraviolet upper room irradiation 
in addition to respiratory protection.  
It has been a great challenge to characterize the airborne transmission route due to 
the difficulty in collecting and analyzing micrometer-sized particles. Studies to date 
have rarely included quantitative analyses of the total viral load. Most sampling 
methods affect the viral viability and result in lower detection of the concentration of 
infectious airborne virus (Huynh et al., 2008). The presence of contaminants could also 
inhibit the laboratory assays. Previous reports on the generation of fine particle 
influenza aerosols by infected persons used instruments that require the subject to 
breathe through a mouthpiece or face mask and/or required unnatural or forced natural 
breathing pattern and do not give an accurate picture of virus shedding by a subject 
breathing normally and coughing spontaneously. Use of a high physical and biological 





breathing, could answer questions about transmission. Some clinical trial studies have 
used experimentally infected volunteers to simulate the naturally infected cases, but it 
is still unclear if these experimentally infected cases will be able to simulate the natural 
ones in all aspects. 
RPDs such as respirators play an important role in the control strategy against the 
transmission of influenza. Experiments to validate the protective device effect on 
influenza transmission require deliberate infection of a susceptible population and 
controlled use of protective equipment. It is extremely difficult and complicated, and 
the feasibility of attaching protective devices to animals is likewise low. Mathematical 
modeling will be a valid tool to evaluate the reduction of risk associated with the 
deployment of a given RPD. Numerous models of various types have been developing 
to simulate the spread of epidemics (Chen and Liao, 2008; Coburn et al., 2009; Furuya, 
2007; Stilianakis and Drossinos, 2010), but no systematic treatment of the effect of 
RPDs has been incorporated into the models. In determining the type of RPD to deploy 
in the epidemic, it is important to have a model which shows the reduction in the 
infection rate that the RPD enables for the given pathogen and population.   
1.2 Research Approaches and Objectives 
The dissertation consists of four major projects, plus a review of relevant literature 
(Chapter 2). The first project is to characterize a human bioaerosol sampler named the 
Gesundheit II, or G-II, for both physical and biological collection efficiency before 
performing on real human subjects (Chapter 3). This is followed by using the device to 





community-acquired influenza virus infection (Chapter 4). The third project is to 
explore the climate effects on infectious influenza virus in human exhaled breath 
(Chapter 5). The fourth project focuses on developing numerical risk assessment 
models from exposure to influenza bioaerosols. The model was developed from the 
existing literature work and modified to include protection factors of the RPDs 
(Chapter 6). Finally, I will give overall conclusions and implications of my results, 
limitations of my work, remaining research questions and possible further work 
(Chapter 7). 
1.2.1 Device Characterization  
The novel exhaled breath aerosol collector named G-II was designed allowing 
natural breathing, coughing, speaking, and singing during sampling. The optimal G-II 
operating parameters were established through a series of experiments. The parameters 
that were taken into consideration are condenser supersaturation ratio, coolant supply 
temperature, and different mass flow rate of the saturated steam. These parameters will 
affect the ability of G-II to collect aerosols in the airstream and the ability to preserve 
virus viability during the collection process. The biological collection efficiency 
comparison between BioSampler and G-II was performed with four types of influenza 
virus. My role in this project was to conduct the characterization experiments and 
interpret the lab results. 
1.2.2 Evaluating Airborne Transmission Mode from Naturally Infected Cases 
An understanding of influenza virus transmission is crucial for public health 





Transmission (EMIT) clinical study is to determine the contribution of aerosols to 
transmission of human influenza virus. Volunteers with influenza-like illness were 
recruited on the College Park campus. As part of a multi-member team, we have 
successfully conducted a study of characterization of respiratory droplets from 
influenza-infected individuals at the University of Maryland campus during the flu 
seasons of 2012-2013. The exhaled breath was collected with the G-II for accurate 
quantification of the influenza virus. 218 pairs of fine (< 5 µm) and coarse (≥ 5µm) 
exhaled breath samples were obtained from 142 subjects and analyzed.  My role in this 
project was sampling human subjects’ exhaled breath, and conducting statistical 
analysis and interpretation of the different resulting datasets.   
1.2.3 Influenza Virus in Respiratory Droplets Produced by Infection Cases from 
Different Climates 
We performed a nested validation study comparing aerosol shedding by infection 
cases from three locations, University of Massachusetts (UML), University of Hong 
Kong (UHK) and National University of Singapore (NUS). These three locations 
represent three types of climates, temperate, subtropical and tropical. The effects of 
outside environmental parameters on human viral shedding are discussed in this 
chapter. We have 7 confirmed H3 influenza infection cases from UHK, 23 confirmed 
H3 and 8 confirmed B cases from NUS, 21 confirmed H3 cases and 16 confirmed B 
cases from UHK. All the exhaled breath and cough aerosols were collected using G-II 





shedding from all three locations was evaluated. My role in this project was performing 
a thorough statistical analysis and interpretation of results.  
1.2.4 Infection Risk Assessment Model 
In order to ascertain a holistic understanding of reduction of risk of influenza 
transmission by using protective measures, we modified the susceptible-infected-
recovered (SIR) epidemic model as presented Stilianakis and Drossinos, 2010 to 
account for the influence of RPDs.  We accounted for the fact that only a fraction of 
the population will likely deploy protective measures by dividing the susceptible 
population into two groups, one of which deploys RPDs and one which does not.  
Similarly, a fraction of the infected population utilizes RPDs, thereby reducing the 
source of pathogens. We first implement our modifications under the idealized 
assumption of a monodisperse aerosol distribution, and then extend the formulation to 
the more realistic case of a polydisperse size distribution. The mathematical risk 
assessment model for influenza transmission will provide a means for improving pre-
clinical assessments of safety and efficacy of personal protection devices used for 
prevention and source control. My role in this project was to conduct the literature 






CHAPTER 2: LITERATURE REVIEW 
2.1 Virology of Influenza  
Influenza viruses are enveloped, single negative-stranded RNA viruses, and 
divided into types A, B, and C according to their antigenic differences. The viruses are 
capable of infecting different species of birds and mammals. Only influenza A and B 
are capable of causing annual epidemics in humans.  Influenza A viruses are subdivided 
into subtypes according to the types of surface protein hemagglutinin (HA) and 
neuraminidase (NA) (Tamura et al., 2005), e.g. influenza A (H1N1), A (H1N2) and A 
(H3N2) are common subtypes in annual human influenza epidemics. The viruses in 
each subtype undergo gradual changes in genetic makeup through point mutations in 
the HA and NA (Tamura and Kurata, 2004). An “antigenic shift” between avian flu 
and human influenza could happen due to such change, and since no immunity has been 
prepared against the modified virus, a global pandemic will arise.  
2.2 Identification of Influenza Virus Infections 
Recently, as reported by Gralton et al. (2013), samples of exhaled breath aerosols 
from both adults and children with symptomatic respiratory infections were collected 
using a 6 stage Anderson impactor and were found to contain viral RNA. In this study, 
during tidal mouth breathing through a mouthpiece, 58% (31/53) of participants 
produced coarse particles containing viral RNA and 80% (42/53) of participants 
produced fine particles with viral RNA (Gralton et al., 2013). The processes by which 
pathogens spread, deposit and initiate infection are highly influenced by the size of the 





dynamics of such naturally generated bio-aerosols include diffusion, impaction, 
interception, or electrostatic attraction (Verreault et al., 2008). The human respiratory 
tract can be divided into three parts, nasopharynx, tracheobronchial region and alveolar 
region. Once the infectious influenza virus aerosol particles reach the respiratory tract, 
the virus will enter the airway epithelium through specific target cells. The viruses will 
attach to host cells that are located in the respiratory tract by binding of the 
hemagglutinin to sialosaccharides on the host cell surface and initiate infection 
(Baigent and McCauley, 2003). If the virus binding occurs in the lower airway and 
alveoli, it leads to more severe illness (Baigent and McCauley, 2003).  
The transmissibility of influenza is also highly influenced by the exposure 
environmental conditions, such as, humidity, temperature, seasonality, settings (indoor 
or outdoor), solar irradiation and air exchange in which the pathogen and host meet 
(Pica and Bouvier, 2012; Tamerius et al., 2013). These factors strongly affect the 
production of influenza-laden particles and also the viability of the virus particles, 
which is linked to risk of infection. Lowen et al., (2007) used guinea pigs to show that 
the infected hosts shed significantly higher quantities of viral particles when exposed 
to lower ambient temperature than those were exposed to higher temperature. Having 
an ultraviolet light in the room could denature the virus, and increasing ventilation 
could dilute the virus in the air. Social distancing through quarantine, isolation of ill 
persons can reduce the rate of transmission successfully. It is believed that airborne 
route is dominant in the temperate climate region due to distinct seasonality. The 
relative lack of seasonality in tropical regions with less variability in temperature and 





A respiratory infection occurs when an infected person spreads the respiratory 
pathogens to a susceptible person. The pathogen carrying respiratory secretions can be 
transferred by making direct physical contact (e.g. shaking hands) or indirectly, when 
the susceptible person makes physical contact with contaminated objects. The 
transmission can also happen by inhaling the respiratory secretions, which are released 
by the infected person in air during breathing, coughing, sneezing or talking. The large 
ballistic droplets can only travel a short distance from the infected person before falling 
to the ground quickly. Small particles with an aerodynamic diameter ≤5 µm that are 
generated either from respiratory tract or the desiccation of large droplets, can stay and 
remain suspended in air for a relatively longer period of time. Nicas et al. (2005) and 
Yang et al. (2007) have confirmed that coughing or sneezing can generate a large 
number of aerosol particles with size greater than 2 µm.  Edwards et al. (2004)  also 
confirmed that exhalation during normal breathing can also generating a large amount 
of aerosols and the majority of them with a size around 1 µm or less. It is believed that 
the aerosol generated from tidal breathing are from the lower respiratory tract (LRT), 
and heterogeneity exists among individuals in aerosol production. Even though per 
cough or sneeze can put out more aerosols comparing with per normal breathing, but 
normal breathing is long term and continuous which should count as a more significant 
fraction in aerosol transmission (Tellier, 2006, 2007).  
Once a person inhales the infectious particles that were exhaled by the infected 
host, there is a chance that the virus may deposit on the receptor of a susceptible cell 
and initiate infection. The air becomes a medium for the transmission of respiratory 





evidence supporting the presence of aerosol transmission in both animals and people. 
Animal studies in ferrets, guinea pigs, mice and monkeys have shown that disease 
developed after exposure to aerosolized influenza virus. The aerosol route of 
transmission has been observed among ferrets placed in adjacent cages in 1941 
(Andrewes and Glover, 1941).  In human volunteer studies (Knight, 1980), a lower 
infection dose was required to cause infection by aerosol than intranasal inoculation. 
In both animal and human studies, evidence showed that infection caused by 
aerosolized virus can lead to more severe disease than intranasal inoculation (Little et 
al., 1979; Mumford et al., 1990). When the virus is deposited in the alveolar region, 
only a small dose can lead to a greater risk for infection.  
2.3 Current Sampling and Analyzing Techniques and Remaining Challenges 
It has been a great challenge to characterize the airborne transmission route due to 
the difficulty in collecting and analyzing micrometer-sized particles. Studies to date 
have rarely included quantitative analyses of total viral load. Most sampling methods 
affect the viral viability and result in lower detection of the concentration of infectious 
airborne virus (Verreault et al., 2008). During the sampling, the presence of 
contaminants could also inhibit the laboratory assays.  
The impaction mechanism is considered as the most common one for particle 
collection. The Stokes number (inertial impaction parameter) is the key parameter in 
impactor design, which influences the efficiency of impaction collector. The air 
sampling technologies also depend on Brownian motion, thermal gradients, inertia of 





diameter of the particles (Verreault et al., 2008). Aerosol measurement requires that an 
aerosol sample be transferred to a collecting medium by withdrawing the sample from 
the environment. The surface tension will act on the medium in the sampler and affect 
the collection efficiency. Particles on the order of micrometer or more have greater 
inertia and gravitational attraction than the smaller ones but are less influenced by 
Brownian motion. Because of that, the bigger particles are more easily diverted from a 
gas streamline and impact on the surface, especially at higher velocities and altered 
angle of the airflow, and the smaller particles easily follow the airflow. The sampling 
techniques have improved greatly over the years, but the issue of lack of efficiency still 
remains because of the wide range of aerodynamic properties of airborne virus. 
Currently, there are a variety of samplers available for bioaersol detection. All 
glass impingers (AGIs) and SKC BioSampler are two commonly used liquid impingers 
for airborne virus sampling. The liquid impingers are efficient for collection of 
submicrometer particles (Fabian et al., 2009). AGIs were designed to accelerate 
particles in the air through the narrow orifice and leading to turbulent deposition of 
particles. It mimics the respiratory tract in terms of deposition of the particles. The 
major difference between SKC and AGIs is that SKC splits the airflow into three 
tangential nozzles and creates a swirling motion in the sampling liquid.  Comparing 
with AGIs, SKC has significantly minimized the reaersolization of the collected 
particles and reduced the particle bouncing. The sampling process for liquid impingers 
is gentle, and the particles impacting on a liquid media can easily maintain their 
integrity and viability. Studies have demonstrated that SKC has a high collection 





300 nm (Willeke et al., 1998). The flow rates are low for the AGIs and SKC, around 
12 lpm.  
Anderson impactors and slit impactors are also common types of impactors used 
for virus air sampling. Anderson impactors can contain up to 6 stages to collect aerosol 
particles with size selection. Bischoff et al. (2013) has used Anderson impactors to 
detect the influenza virus up to six feet from an infected patient’s head. A slit impactor 
was used during the SARS outbreak in 2003 with great success. It operates by 
impacting particles on a rotating dish and can recover the viruses with a liquid layer on 
top of the culture medium. The culture media on the Anderson impactor and slit 
impactor can introduce contamination and drying over time. Several filters operate with 
basic mechanism including interception, inertial impaction, diffusion, gravitation 
settling and electrostatic attraction (Hinds, 1999). These filters are made out of different 
materials such as cellulose, polycarbonate and gelatin with the ability to collect 
airborne particles. Fabian et al. (2009) showed that influenza viruses quickly lose 
infectivity on filters. 
The National Institute for Occupational Safety and Health (NIOSH) has developed 
a cyclone BioSampler that operates by using centrifugal force to push airborne particles 
into a solid surface using their inertia. This NIOSH sampler operates at 3.5 L/min and 
can be used as a personal or area sampler. The particles were collected in three stages, 
4μm and above on the first stage, 1-4 μm in the second stage and the remaining were 
collected on a backup filter. Filed and laboratory studies have confirmed the influenza 
virus recovery ability of NIOSH (Blachere et al., 2007, 2009; Cao et al., 2011; Lindsley 





delivering a small liquid effluent flow rate of highly-concentrated hydrosol. The 
collection efficiency was proved to be 85% for particle sizes larger than 2 µm at the 
0.1 mL/min liquid effluent flow rate for 100 L/min air flow rate (McFarland and 
Burroughs, 2011; McFarland et al., 2010). The submicron collection efficiency has 
been tested to be low for wetted wall cyclone (Kesavan et al., 2008). 
Although there are many different samplers designed to collect airborne influenza 
virus, the sampling method is still remaining challenging in the field study due to 
variety effects. The dry samplers have been shown to result in damage and desiccation 
of the viruses. Cao et al. (2011) showed that NIOSH BioSampler performed 
significantly worse at maintaining infectious airborne virus than the SKC BioSampler 
due to the desiccation and degradation of the virus over time. For prolonged sampling, 
it is important to preserve the activity of the virus and also maintain a high collection 
efficiency.  The liquid media filled samplers can easily dry out over time under low 
humidity and the gel filters can also likely to dissolve under high humidity. The 
evaporation during sampling can alter the characteristic of the media. The bubbling 
liquid during sampling can easily reaerosolized the viral particles. In summary, the 
limitations of current samplers include the inability to separate particles based on size, 
limited sampling time, and low biological collection efficiency. In order to accurately 
collect and detect an individual’s virus aerosol shedding, a long-term sampling strategy 
needs to be explored.  
Infective influenza virus can be quantified using a fluorescent focus assay. The 
fluorescent focus assay binds fluorescently labeled antibody to viral proteins produced 





infected cells, but the detected sensitivity is too low and many viable virus particles 
could be missed. When viral concentration in the samples is low, technology such as 
polymerase chain reaction (PCR) and real-time quantitative polymerase chain reaction 
(RT-qPCR) are popular methods to detect the presence of viruses in collected samples. 
Comparing with other enzyme-linked immunosorbent assays, PCR has been considered 
as the most effective, sensitive and specific for detecting samples with low viral 
concentrations (Elden et al., 2001). Using this technology, Fabian’s group has 
successfully detected influenza virus RNA in aerosol particles generated by the patient 
wearing a facemask (Fabian et al., 2008). The limitation of PCR is it cannot it cannot 
determine if the detected viruses are infectious or not.   
2.4 Mathematical Modeling of Influenza Epidemics and Non-Pharmaceutical 
Intervention 
Mathematical models have made considerable contributions to the understanding 
of influenza infection. In planning the response to a future or ongoing epidemic, 
development of an infection risk assessment model is essential.  Quantitative infection 
risk assessment will incorporate both demographical and epidemiological effects 
during an outbreak to estimate the infection risk of a population (Sze To and Chao, 
2010). The model will provide a means for improving pre-clinical assessments of safety 
and efficacy of personal protection devices used for prevention and source control. 
Several influenza transmission models have been constructed in the literature 
combining both physical dynamics and the biological processes to estimate the risk. 





the risk of infection (Atkinson and Wein, 2008). One of the most used models is Wells-
Riley exponential model, derived from the Reed-Frost Equation (an early stochastic 
model) (Sze To and Chao, 2010). It is a predictive model that quantitatively evaluates 
airborne infection risk in a single generation of an outbreak. The Wells-Riley model 
incorporates the source strength in terms of a quantum of infection (Sze To and Chao, 
2010). It does not give the direct access to identify the number of pathogens that 
constitute the source strength. The Wells-Riley model also requires measurement of 
outdoor air supply rates, which is hard to define as it often varies with time. 
Deterministic models have been most widely used for respiratory disease 
transmission models, in which SIR (susceptible-infected-removed), SEIR (susceptible-
exposed-infected-removed) and Carrier State Models are the most notable ones 
(Keeling and Rohani, 2008). The choice of which model to use depends on the 
characteristics of the disease and the purpose of the model. 
The classic compartment SIR model is an epidemiological model which was 
developed by Ronald, et al. in the early twentieth century (Anderson, 1991). The model, 
which has been widely applied, consists of several differential equations coupling the 
changes in the population of susceptibles (S), the exposed population (E), the 
population of infection cases (I), and the population of formerly infected, now 
recovered to an immune state (R). The SIR model can quantify risk by considering 
source strength in terms of pathogen numbers, assuming the 50% infectious dose is 






Control of influenza transmission during an epidemic is a major issue. Both 
immunization and the proper use of respiratory protective equipment (RPD) are 
important in preventing transmission of communicable respiratory illness. Vaccine use 
can cut down some of the risks of the transmission but not completely. In a recent study 
by the CDC, it was shown that flu vaccination was responsible for a 70% reduction in 
infections among all population groups during the 2011-2012 flu season (Centers for 
Disease Control and Prevention (CDC), 2013). During normal seasons with gradual 
revolution of influenza virus, vaccine can be effective. But vaccine is normally not 
available in time for a new virus strain to prevent virus spread and wearing RPD could 
reduce the risk of influenza transmission further. Thus, RPDs such as respirators may 
constitute an important element of the control strategy against the transmission of 
infectious diseases.  In determining whether to deploy a given RPD to protect a specific 
population against a certain pathogen, including whether to allocate substantial 
resources to stockpile RPDs against a possible future threat, realistic estimates of the 
reduction of risk associated with the use of the RPD in the scenario of interest is 
important.  In evaluating the reduction of risk associated with deployment of a given 
RPD, important parts of the assessment include determination of the intrinsic 
penetration of the device (Technologies et al., 2010) which is governed by the 
microscopic properties of the barrier, and the amount of leakage due to imperfect fit 
(Coffey et al., 2004; Lee et al., 2004) between a particular facial profile and the RPD. 
Another important part of the risk assessment for RPDs is an estimate of the change in 
the infection rate associated with the change in pathogen transport introduced by the 





uninfected person attempting to reduce the intake of pathogens or an infected person 
attempting to reduce the output.  While numerous models of various types have been 
developed to simulate the spread of epidemics, no systematic treatment of the effect of 
RPDs has been incorporated into the models. 
Of particular interest for RPD evaluation is the transmission of disease by inhalable 
respiratory droplets. To serve the purpose of monitoring the source strength in the 
influenza airborne transmission, a model that is well suited to estimate the spread of 
disease by inhalable respiratory droplets is the modified deterministic SIR epidemic 
model. This model was developed by Stilianakis and Drossinos (2010) (SD) and takes 
the inhalable droplets as the transmission vector, assuming a closed, homogeneously 
mixed population. The time course for the susceptible, infected, and recovered 
populations was derived in the SD model using parameters from experimental 
evidence. This model did not address the effect of any type of prevention in the 
influenza infection.   
Myers et al. (2016) take the effect of different types of RPDs into the SIR model 
by SD, and when the growth of the infected population will occur is evaluated for a 
given protection strategy for adult and child populations separately. The model also 
indicates how aerosol size distribution in the polydisperse exposure affects the growth 
of the infected population. In the SIR models, the influence of RPDs can accounted for 
in a systematic manner in the parameters within the system of differential equations.  
Relevant parameters of the model include the droplet production rate, gravitational 
settling rate, deposition probability, and a number of pathogens per droplet, all of which 





making decisions for a) quantifying the risk reduction from use of RPD and b) help 





CHAPTER 3: EXHALED BREATH COLLECTION AND ANALYSIS 
OF VIRUS SHEDDING RATES USING G-II BIOAEROSOL 
COLLECTOR 
3.1 Abstract  
We performed a series of experiments to characterize the ability of the exhaled-
breath bioaerosol collector (G-II) to collect and preserve culturability of four 
biologically different influenza viruses. We used those data to calculate the strength of 
the infectious source. Experiments were designed to characterize physical collection 
efficiency and ability to preserve infectivity. Optimal collection efficiency was 
achieved when the G-II was operated with a supersaturation ratio of 2.6 or higher. 
Infectivity was increased when the inlet air temperature was 24˚C or higher and the 
relative humidity of the inlet air was 65% or higher. The G-II preserved infectivity as 
well or better than the commercial SKC BioSampler. Therefore, the G-II can be 
successfully used to collect samples from subjects infected with influenza without prior 
knowledge of influenza subtype. Using the data collected from laboratory samples and 
samples collected from three infected subjects, we demonstrate a calculation of the 
quantity of virus released into aerosols by influenza-infected individuals.  
3.1.1 Practical Implications 
This study describes the instruments and process necessary for quantification of 
aerosolized influenza virus from infected individuals. The G-II can be used to study 





information, should airborne transmission be found a significant contributor to 
propagation. These results will have implications on determining correct ventilation 
rates, air distribution strategies, and deployment and effectiveness of air cleaning 
technologies. The most important application would be in the design of heating, 
ventilation and air conditioning systems in hospitals and indoor environments with high 
occupant densities. 
3.2 Introduction 
Pandemic influenza remains an important global threat. The most recent influenza 
pandemic of 2009 showed how rapidly the virus can spread worldwide. Influenza 
transmits by contact, droplet and airborne modes. Aerosol transmission of influenza 
was first reported between ferrets in 1941 (Andrewes and Glover, 1941). Alford et al., 
1966 is the only study that addressed the question of the minimum infectious aerosol 
dose in humans (0.6-3 TCID50). In natural settings it is difficult to identify the route of 
transmission of individual cases and the relative importance of each of the modes is 
still a topic of disagreement. Several authors have concluded that the airborne mode is 
the key pathway of influenza transmission (Fabian et al., 2008; Gralton et al., 2013; 
Tellier, 2009; Weber and Stilianakis, 2008). Reanalysis by Cowling et al., 2013 of 
previously collected data suggested that airborne transmission might be a major factor, 
especially in causing more severe infections. In contrast to these studies, a review by 
Brankston et al., 2007 and study by Tang et al., 2014 suggest that airborne transmission 
does not contribute significantly to influenza transmission. Knowledge of the infectious 
influenza virus aerosol is critical to 1) understand the role of aerosols in influenza virus 





However, there are few studies that examine this critical issue. 
The initial description and characterization of the Gesundheit-II (G-II) human 
exhaled aerosol collector, by McDevitt et al., 2013, described the efficiency of 
collecting a virus known to have a spherical morphology (A/Puerto Rico/8/1934 
(H1N1), PR8). The objectives of the present study were: 1) to quantify all the losses 
encountered during the sample collection, processing and analysis to enable more 
accurate determination of virus shedding rates from infected volunteers, 2) to extend 
the analysis to virus strains previously shown to have a filamentous morphology, and 
3) to extend the analysis to influenza B virus.  
During the quantification of losses, we examined the impact of the G-II operating 
parameters on the biological and physical collection efficiency, and quantified losses 
that take place during sample processing. Because human clinical strains exhibit 
filamentous morphology, we used two strains previously shown to produce filamentous 
virions. We compared the results to those obtained using viruses known to have a 
spherical morphology. In the final part of the present study, we used data obtained in 
the experiments and information from the literature to calculate viable virus shedding 
rates by three influenza infected volunteers.   
3.3 Methods 
3.3.1 Equipment 
A schematic of the G-II is presented in Figure A1. In this study we examined 





quantified loses encountered during the sample preparation and analysis, and finally 
we introduced a method to calculate the amount of virus shed by infected volunteers. 
Pilot collection of exhaled breath samples from influenza-infected subjects was 
conducted after collection parameters were optimized.  
A P-Trak ultrafine condensation particle counter (TSI Inc, Shoreview, MN) was 
used to measure aerosol concentration at various locations in the G-II. The P-Trak can 
measure cumulative particle concentrations in the particle size range from 0.02 µm to 
1 µm and concentration up to 5 x 105 particles/cm3.  The sample flow rate of the P-Trak 
was 1 L/min. A pump with a sampling flow rate of up to 30 L/min (SKC, Eighty Four, 
PA) was used to draw air samples from the G-II airstream. Since the sampling pump 
draws much higher airflow rate then necessary for P-Track measurement, the airstream 
coming out of the pump was connected to the 50 mL sterile vial. The sterile vial served 
as an air reservoir with one inflow stream from the sampling pump and two outflow 
streams. One outflow stream was connected to the P-Trak and the other served as a 
relief for the excess air.  
In order to maintain conditions necessary for sub-micron exhaled breath aerosol 
(EBA) sampling, a booth was used to segregate the sampling environment from the 
immediate surroundings. The air in the booth was heated (26.7 oC) and humidified 
(RHbooth = 80 %). Air from the booth was pulled into the cone (aerosol-sampling inlet) 
with the flow rate of 125 L/min and passed through an inertial impactor designed to 
have 50 % sampling efficiency for particles with aerodynamic diameter of 5 µm 





the air stream. Adding saturated steam increased temperature of the mixture to 27.2 °C. 
Subsequently, the air stream with suspended aerosols was then rapidly cooled down to 
8 °C in the condenser. This produced supersaturation conditions in the airstream and 
allowed the submicron particles in the aerosol to serve (point 3 on Figure A1 and A2). 
This rapid cooling induced aerosol growth and allows for submicron particle collection 
using a 1 µm inertial impactor.  
The collection efficiency of the G-II was compared with the SKC BioSampler 
(SKC, Eighty Four, PA) for several influenza strains. The SKC BioSampler was filled 
with 20 mL PBS/0.1% BSA. The sampling flow rate was 12.5 L/min. Sampling was 
performed for 10 min to avoid evaporation of the liquid collection medium (Lin et al., 
1999) at the flow rate of 12.5 L/min. 
A six-jet, Collison nebulizer (BGI Inc., Waltham, MA, USA) filled with 20 ml 
liquid buffer with suspended virus and pressurized with N2 at 1.38×105 Pa (20 psi) was 
used to create aerosols containing virus particles. Aerosols suspended in the airstream 
moved through the pipe connected to the nebulizer on one side and open on the other. 
The open end of the pipe was positioned in the center of the cone allowing aerosols to 
be discharged into the cone at a supply flow rate of 2.5 L/min. 
3.3.2 Viruses 
Influenza viruses A/California/04/2009 (pandemic H1N1), A/Puerto Rico/8/1934 
(H1N1), A/Udorn/1972 (H3N2) and B/Lee/1940 were used to test whether the G-II 
collection process is capable of preserving infectivity of different viruses. The 





will be abbreviated PR8, A/Udorn/1972/ (H3N2) will be abbreviated A/Udorn, 
A/California/04/2009 (pandemic H1N1) will be abbreviated A/California, and 
B/Lee/1940 will be abbreviated B/Lee. These viruses were chosen because they 
represent a range of properties that could be encountered by the sampler. PR8 is a 
laboratory strain originally isolated in 1934. This virus grows exclusively as spherical 
particles in tissue culture, and has been used previously to test collection devices 
(Singer et al., 1972). A/California and A/Udorn grow as a mixture of spherical and 
filamentous particles in tissue culture, and A/California is within 4 passages of clinical 
isolation.  B/Lee is an influenza B laboratory strain isolated in 1940. For each virus, 
stocks were diluted to 20 ml in PBS/ 0.1% BSA. Final virus concentrations were 
5.5×105 fluorescent focus units (FFU) per ml.  
3.3.3 Laboratory Analysis 
At the end of an EBA collection session, the Teflon substrate in the 5 µm inertial 
impactor was removed and placed in a sterile vial. The surface of the substrate was 
scrubbed with a Copan flocked nylon swab wetted with phosphate buffered saline 
supplemented with 0.1% bovine serum albumin (PBS/0.1% BSA). The tip of the swab 
was cut off in 1 ml PBS/0.1% BSA and the tube was vortexed for 1 minute at full speed 
prior to removal of the swab tip. The amount of virus in resulting sample was 
quantitated by real-time RT-PCR. The 1 µm inertial impactor collected approximately 
125 ml of condensate sample in the reservoir placed below the impaction plate. After 
collection was completed, sample was removed from the reservoir with a sterile syringe 





Centricon Plus-70 centrifugal ultrafiltration device (Millipore, Billerica, MA) and 
analyzed by RT-PCR and focus assay.  
Real-time Reverse Transcriptase Quantitative Polymerase Chain Reaction (Real-
time qRT-PCR) measures the total number of copies of virus genome per sample. RNA 
from 200 µl of each sample was extracted using the Minelute Virus Spin kit (Qiagen) 
and eluted in 50 µl sample buffer. 10 µl was analyzed by real-time RT-qPCR using 
primer/probe sequences designed at the US Centers for Disease Control and 
Prevention. Standard curves were constructed using a dilution series of a PR8 stock 
that had been quantitated by electron microscopy (Advanced Biotechnologies Inc.). 
In order to quantify the amount of infectious virus in each sample, fluorescent 
focus assays were used. 10-fold dilutions of the sample were made in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 1 µg/ml N-acetyl trypsin and 
0.1% BSA. Madin-Darby canine kidney (MDCK) cells were grown in 24-well plates, 
and after washing thoroughly, 150 µl of each virus dilution was incubated with the cells 
in triplicate at room temperature for 1 h. After incubation, 300 µl DMEM supplemented 
with 10% fetal bovine serum was added to each well. This serves two purposes. It 
nourishes the cells to try to maintain cell morphology, and it limits infections to a single 
round by inactivating the trypsin in the inoculum. Cells were then incubated at 37 °C 
for 8 h prior to fixation with ice-cold 80% acetone. Following rehydration, cells were 
stained for immunofluorescence microscopy with anti-NP antibodies (AA5h-Abcam 
and sc-57885-Santa Cruz Biotechnologies) and an AlexaFluor488-conjugated goat 





Olympus inverted microscope fitted with an X-cite 120 LED fluorescence light source 
(EXFO Photonic Solutions). The amount of virus in the original sample was calculated 
based on the dilution plated and the number of positive cells in the well or in the area 
of the well examined.  
3.3.4 Experimental Design 
This study contains 3 sets of experiments, designed to quantify shedding rates of 
airborne virus released by the influenza-infected person. The first set of experiments 
was performed to determine optimal operating parameters for maximizing physical and 
biological collection efficiency. The second set of experiments investigated collection 
performance for four different types of influenza viruses. The third set of experiments 
was designed to characterize losses during the sample preparation and analysis, to 
develop a method of calculating virus shedding rates based on the measured results.  
The G-II operates on the concept of using water condensation to grow sub-micron 
particles (which may contain virus particles) to a size that can be easily and efficiently 
collected (McDevitt et al., 2013). In order to optimize collection by the G-II, we 
performed two types of experiments. The objective of the first experiment was to 
determine what quantity of water vapor is required to be in the air to grow particles via 
condensation to large enough size to reach high collection efficiency. The objective of 
the second experiment was to determine the optimal set of operating conditions (booth 
temperature, humidity, and steam production) to reach sufficient quantities of water 





Supersaturation ratio is defined as the actual water vapor pressure divided by the 
equilibrium water vapor pressure.  In the G-II condenser, supersaturation ratio is 
effectively the ratio of the water vapor pressure of the mixture of air and saturated 
steam immediately before stream enters the condenser divided by the water vapor 
pressure immediately after it exits the condenser (Sioutas et al., 1995). This parameter 
is influenced by conditions coming from the booth where the subject sits, mass flow of 
saturated steam injected into the airflow, and amount of cooling that takes place in the 
condenser. The supersaturation ratio determines the increase in diameter of the particles 
from their initial size when they enter the condenser until they exit the condenser. 
The G-II was operated at a flow rate of 125 L/min. Aerosols with diameters from 
0.02 µm to 1 µm, present in the ambient air, were used to investigate the relationship 
between supersaturation ratio and the physical collection efficiency. Different air – 
steam mixture conditions above the condenser were achieved by varying the booth 
temperature (Tbooth), the relative humidity in the booth (RHbooth) and mass flow rate of 
saturated steam injected in the G-II. Each measurement was performed for 15 min after 
steady state was reached.  Particle concentration was measured with a P-Trak at two 
locations. The upstream measuring point was at the aerosol collector inlet (cone) and 
the downstream measuring point was after the fine fraction collector. The ratio of 
particle concentrations after the 1 µm impactor and at the cone is used to calculate 
collection efficiency η of the G-II fine fraction collection  
𝜂𝜂 = 1 − 𝐶𝐶𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 1µm impactor 
𝐶𝐶𝑐𝑐𝑑𝑑𝑑𝑑𝑑𝑑





During an exhaled-breath collection session, subjects must sit in the booth and 
breathe into the cone for 30 minutes in order to collect enough exhaled breath to reliably 
detect exhaled influenza virus using the current laboratory detection methods. To 
maintain some level of thermal comfort for subjects, we decided to reduce heating and 
humidification of the booth and substitute injection of a larger quantity of saturated 
steam to reach the appropriate supersaturation ratio. The mixture of the booth air and 
saturated steam must have a temperature of 27 ℃ and humidity ratio of 0.02735 
kgwater/kgair to achieve the required supersaturation ratio (≥ 2.6) for physical collection 
efficiency above 90%. Based on the ideal gas mixing law, required mass flow rates of 
saturated steam were calculated for a range of booth air conditions. The experiment 
described below is designed to test whether changes of saturated steam mass flow rate 
have an impact on virus viability. 
G-II collection efficiency for coarse (≥ 5 µm) and fine (< 5 µm) aerosol fractions 
for one set of operating parameters was described in McDevitt et al. (2013). In this 
chapter, we selected the conditions in the booth range from surrounding ambient 
conditions to warm and humid environment conditions (eg. Tbooth = 20 ℃, RHbooth = 
50% to Tbooth = 27 oC and RHbooth = 70%). The booth conditions were chosen to 
maintain a supersaturation ratio of 2.6 or higher with the changing of saturated steam 
flow rates. Three saturated steam mass flow rates were explored in this experiment: 
3.1×10-5 kg/s, 4×10-5 kg/s and 5.4×10-5 kg/s. Virus was aerosolized with the collison 
nebulizer for 10 min and released in the cone with the flow rate of 2.5 L/min. Virus 





condensate was collected from the reservoir. Each experiment was repeated 3 times for 
each of the conditions tested. 
A/California, PR8, A/Udorn and B/Lee influenza virus were aerosolized with a 
Collison nebulizer and released into G-II cone as described in the previous section. The 
G-II was operated under conditions that produced physical collection efficiency above 
90%. Virus was collected in PBS/0.1% BSA. After 10 min, aerosolization was stopped 
and the condensate was collected from the reservoir. Experiments were repeated 3 
times for each virus. Between each of the experiments each of the G-II parts with the 
exception of the condenser was decontaminated with 10% bleach followed by thorough 
rinsing with deionized water. Since the condenser could not be submerged in the bleach 
solution, it was decontaminated with a 70% ethanol spray instead.  
To quantify the losses on the Teflon impactor, the 5 µm Teflon substrate was 
spiked with a known amount of influenza virus for each strain used (between 1.0×105 
to 8.6×105 virus particles per impactor) in a level 2 biological safety cabinet. The 
Teflon substrate was allowed to air dry until all of the liquid had evaporated. The Teflon 
substrate was then placed in the G-II for 30 minutes to simulate conditions during the 
EBA collection. After 30 minutes, the Teflon substrate was removed the surface of the 
substrate was scraped with a Copan flocked nylon swab wetted with PBS/0.1% BSA. 
The tip of the swab was cut off in 1 ml PBS/0.1% BSA and the tube was vortexed for 
1 minute at full speed prior to removal of the swab tip. The amount of virus in the 
resulting sample was quantitated by real-time RT-PCR. That number was then 
compared to the total number of virus particles present in the solution used to coat the 





The total number of influenza virus particles present in the coarse fraction of 
exhaled breath can be calculated based on the number of virus particles detected by 
RT-PCR method and Teflon substrate recovery efficiency:   
𝑁𝑁𝐶𝐶𝐶𝐶 =  
𝑛𝑛𝑞𝑞𝑞𝑞𝑞𝑞𝑞𝑞𝑐𝑐𝑞𝑞
𝜂𝜂𝑐𝑐𝑞𝑞∙𝜂𝜂𝑑𝑑𝑑𝑑𝑐𝑐𝑑𝑑𝑟𝑟𝑑𝑑𝑑𝑑𝑟𝑟
  (2) 
NCF represents the total number of viruses released in the coarse fraction by the 
infected person; nqPCRcf is the number of virus particles detected with RT-PCR method; 
ηcf is the collection efficiency of coarse fraction; ηrecovery is the experimentally 
determined Teflon substrate virus recovery efficiency. 
During a 30 min sample collection from a human volunteer, 120 mL to 150 mL of 
condensate gets collected from the bottom reservoir. This volume of liquid is unwieldy, 
and likely to be too dilute to detect infectious virus particles shed in exhaled breath. 
Therefore, it was deemed necessary to concentrate the condensate sample prior to 
analysis.  
In order to quantify possible losses during the concentration process 2.2x107 real-
time PCR units of A/California were suspended in 120 mL of PBS/0.1% BSA.  This 
solution was concentrated as described and the amount of virus in the concentrated 
sample was measured by real-time RT-PCR.  
Similar to the coarse fraction, total number of virus particles in the fine fraction 
can be calculated based on the real-time RT-PCR results of the collected sample. 








NFF represents the total number of virus particles released in the fine fraction by 
the infected person; nqPCRff  is the number of virus particles detected in the sample; ηff 
is the experimentally determined fine fraction collection efficiency; ηsc is the 
experimentally determined efficiency of condensate concentration.  
The number of viable virus particles can be calculated using 





VFF represents number of viable virus particles in the fine fraction. Quantification 
of these processes was conducted to properly account for the viable virus particles, 
when we calculated amount of viruses shedded in aerosols by influenza infected people 
based on the measured virus quantities. 
𝑇𝑇
𝐼𝐼�  is the experimentally determined ratio of the total virus particle number to the 
number of infectious particles in the collected sample, which equals to the PCR results 
vs. focus assay results. Pan et al., 2016 showed that BioSampler has viable collection 





efficiency is similar to BioSampler. Results from Pan et al., 2016 were also used to 
calculate the amount of viable virus released from the source of infectious particles.  
3.4 Results and Analysis 
3.4.1 Optimization of The G-II Collection Parameters 
The relationship between fine fraction collection efficiency and supersaturation 
ratio follows the “S” shape curve (Figure 3.1) analogous to the inertial impactor 
collection curve plotted against particle diameter. The number of particles removed 
from the air stream with the fine fraction collector depends on the particle growth 
achieved by rapid cooling in the condenser.  
The results in Figure 3.1 showed that 50% physical collection efficiency is 
achieved with supersaturation ratio of 2. This result suggests that 50% of the ambient 
aerosols in the range of 0.02 µm – 1 µm (measurement range of P-Track) were able to 
 





grow beyond the size collected with fine fraction collector. Physical collection 
efficiency above 90% is achieved for supersaturation ratio of 2.6 and above. Results 
also suggested that increasing supersaturation ratio beyond this point does not increase 
collection efficiency. These conditions should be maintained during the influenza 
infected participants exhaled breath collection. 
Calculations presented in Figure 3.2 are based on the ideal gas mixing law. RHbooth 
is depicted on the x-axis and Tbooth are presented with individual lines. The required 
saturated steam mass flow rates corresponding to the fine fraction collection efficiency 
above 90% are plotted on the y-axis. We performed several experiments (results are 
superimposed on the Figure 3.2) to validate these calculations.  
 
Figure 3.2. Required saturated steam mass flow rate for maintaining physical collection efficiency 






Results depicted in Figure 3.3 represent the ratio between total number of virus 
particles in the sample and number of viable viruses in that sample (T/I ratio) for 
A/California virus at different injected steam flow rate. When this type of 
representation (T/I ratio) is used, a larger T/I ratio indicates reduction of virus viability. 
Results on Figure 3.3 show that when steam was injected with mass flow rates of 
3.1×10-5 kg/s and 4×10-5 kg/s T/I ratios were very similar, but when 5.4×10-5 kg/s was 
injected, the viability of collected aerosolized influenza virus decreased between 2.4 to 
3.6 times. When 5.4×10-5 kg/s of steam was injected, most probably virus particles had 
longer contact time with the hot steam before they mixed with the air stream and this 
caused virus inactivation. This issue requires further investigation. The results 
presented in Figure 3.3 suggest that during sample collection, the saturated steam 
should not be injected at a mass flow rate higher then 4×10-5 kg/s. Because of this 
finding, the booth should be maintained at 24 ℃ or higher and RH of 65% or higher 
based upon the supersaturation ratio calculation. 
 






Conditions of air leaving the condenser depend on the amount of cooling that takes 
place in the condenser. Coolant flow rate was constant; hence cooling condenser-
cooling capacity was determined by coolant supply temperature. This suggest that 
supersaturation ratio will depend only on the coolant supply temperature.  
During the expiratory droplets collection chiller that regulated coolant temperature 
rejected heat into the surrounding ambient air. This can cause increase of ambient air 
temperature and subsequently can causes reduction of chiller cooling capacity. 
Reduction of cooling capacity causes increase of the coolant supply temperature and 
change in collection efficiency. Increase of ambient temperature and subsequent 
reduction of cooling capacity represents limitation of the experimental setup used in 
the present study, hence it is very important to characterize collection efficiency that 
can occur during suboptimal operation. Knowledge of collection efficiency during 
suboptimal conditions is important in order to properly calculate initial viral shedding 
rates based on the measure amount.  
Process occurring in the condenser is depicted with point 2 and point 3 on Figure 
A1 and Figure A2. In order to quantify changes in the physical collection efficiency 
caused by the variation of the cooling fluid supply temperature collection efficiency 
measurements (as described in the previous section) were performed while coolant 
supply temperature was varied between -2.2 ℃ and 1.1 ℃.  
G-II physical collection efficiency was tested for cooling fluid supply temperatures 
between -2.2 ℃ and 1.1 ℃. Results of Figure 3.4 show that physical collection 





very important result because it indicates that in order to keep physical collection 
efficiency high during the collection of expiratory aerosols from the subjects infected 
with Influenza cooling fluid supply temperature should not be increased above -1.5 ℃.  
Results also indicate that during collection of the expiratory samples, cooling fluid 
supply temperature should be recorded because physical collection efficiency can be 
reduced up to 20% if cooling fluid supply temperature is increased for 2 ℃. This is 
very important especially when viral shedding rates are calculated based on the amount 
of virus detected in the collected sample.    
 






3.4.2 Biological Collection Efficiency for Four Types of Influenza Viruses  
The results presented in Figure 3.5 show that G-II collected 77% ± 6%, 93% ± 
24%, 91% ± 14%, and 117% ± 15% compared to BioSampler for A/California, PR8, 
A/Udorn and B/Lee respectively. These results suggested that G-II can be effectively 
used for sampling different types of influenza viruses, and can be used effectively for 
collection of human exhaled breath from the influenza infected subjects.  
T/I ratios presented in Table 3.1 showed that the G-II can preserve virus viability 
for A/California, PR8 and A/Udorn. T/I ratios for G-II collected sample were compared 
to those collected by the SKC BioSampler, and the ratios were very close. G-II 
performed even better than the BioSampler with PR8. T/I ratio was not available for 
B/Lee, since aerosolizing B/Lee with the Collison nebulizer cannot preserve the 
 
Figure 3.5. Collection efficiency comparison between BioSampler (BS) and G-II for 






viability of the virus. The results for influenza A viruses showed that sampling with the 
G-II preserves viability of collected virus particles.  
3.4.3 Quantifying Amount of Virus Released by Influenza-Infected Person 
When viruses deposited on the Teflon substrate were removed with Copan swabs, 
the RT-PCR results showed variability in recovery among viruses used in the 
experiment. A/California was recovered with 16% efficiency, PR8 with 31% 
efficiency, A/Udorn 33% efficiency and B/Lee with 41% efficiency (Figure 3.6). The 
average recovery was 30%. This result indicates that amount of virus impacted on the 
Teflon substrate was 3.3 times greater than that measured with the RT-PCR method.  
Real-time RT-PCR results showed that the ratio of the amount of viruses detected 
in the concentrated sample and the amount originally placed in the 120 mL of 1% PBS-
BSA was between 0.98 and 1.02. Taking into account measurement uncertainty, the 
results show that sample concentration did not introduce additional losses. Similarly, 
Table 3.1. T/I ratios for A/California/04/2009, A/Puerto Rico/8/1934, A/Udorn/1972 and B/Lee/40 
with both G-II and BioSampler (BS)  
 Virus types 
A/California PR8 A/Udorn B/Lee 
BS T/I 
ratio  (1.39 ± 0.70) ×10
3 (4.17 ± 1.63) ×105 2.71 ± 0.44 NA* 
G-II T/I 
ratio (3.85 ± 1.81) ×10
3 (3.71 ± 1.31) ×102 3.53 ± 0.49 NA* 







focus assay results show that virus infectivity is not influenced by the process of sample 
concentration.  
Average G-II operating parameters during sample collection are presented in Table 
A1 in the Appendix A. Based on the results from previously described studies, 
experimental values used for calculation of viral shedding rates are:  
ηrecovery = 0.30; ηsc = 1; ηcf = 0.5; ηff = 0.92;  𝑇𝑇 𝐼𝐼� = 350 
Equation 2 was used to calculate the total number of viruses collected on the 5 μm 
impactor. This represents the coarse fraction in the collected sample. Equation 3 was 
used to calculate total number of viruses collected in the fine fraction condensate. The 
 
Figure 3.6. Virus recovery efficiency for Teflon substrate with A/California/04/2009, 






number of live viruses collected in condensate sample was calculated using Equation 
4. Measured quantities and calculated source strengths are presented in Figure 3.7.  
The results presented in Figure 3.7 showed that, after collection of EBA from three 
subjects, their fine fraction samples could be corrected based on our experiments. Up 
to 3.7×105 viruses can be release into the indoor environment in 30 minutes, and up to 
2.7×102 of the released viruses could be viable influenza viruses.    
3.5 Discussion 
Based on the three samples from influenza-infected subjects, we knew that the G-
II can quantify viral shedding rates efficiently when an infected person acts as a source 
of viruses in the indoor environment, and the virus viability can still be preserved 
during the sampling.  From the literature, quantification of the virus content in the 
 
Figure 3.7. RT-PCR, Focus Assay results for 3 samples collected from the influenza 







exhaled air has been done by several groups. (Fabian et al., 2008; Gralton et al., 2013; 
Hatagishi et al., 2014; Huynh et al., 2008; Lindsley et al., 2010; Milton et al., 2013; 
Stelzer-Braid et al., 2009).  The NIOSH BioSampler has been characterized for study 
of influenza aerosols (Blachere et al., 2007; Cao et al., 2011). That sampler with its low 
flow and small size is well suited to personal exposure sampling, but requires use of 
artificial means, such as breathing or coughing into a volume spirometer, to capture 
exhaled breath for direct analysis. The application of a six-stage Andersen sampler by 
(Gralton et al., 2013) similarly required subjects to exhale or cough through a 
mouthpiece. The electret mask system developed by Stelzer-Braid et al., 2009 gives an 
excellent measure of overall virus shedding, but does not distinguish the aerosol 
component of the shed virus.  
Cough released aerosols were collected in a 10-liter piston style accumulation 
chamber and then sampled by NIOSH BioSampler and SKC BioSampler in studies by 
Lindsley et al. (2010) and Lindsley et al. (2015). Forcing cough through a mouthpiece 
is a limitation of the collection method used in two studies by Lindsley et al.  The 
commercially available RTube® exhaled breath condensate sampler was used by 
Houspie et al. (2011) to collect exhaled aerosols through a mouthpiece from subjects 
with influenza illness like symptoms.  Hatagishi et al. (2014) used a single stage 
Sartorius MD8 portable sampler with gelatin filter and cone shaped collection nozzle 
to collect forced cough aerosols from influenza-infected patients.  Limitations of 
collection equipment used by Hatagishi et al. (2014) were the inability to distinguish 
viral content in ballistic droplets versus aerosols, low overall viral gene recovery rate 





Valuable information has been obtained with all of these sampling methods. 
However, to accurately estimate the quantity and size distribution of virus aerosol shed 
into an indoor environment, a device that does not restrict respiratory activities, collects 
aerosol with high efficiency and preserves viability is needed. Influenza studies so far 
have not reported quantities of virus released into the indoor air by infected building 
occupants through expiratory activities. Reported studies have only used 
epidemiological data to calculate viral load in terms of quanta (rate infectors generate 
infectious doses) (Rudnick and Milton, 2003; Sze To et al., 2008; Zhu et al., 2012) and 
then based on quanta, calculated effectiveness of engineering and non-engineering 
control measures. Development of aerosol sampling technology and methods for 
quantification of source strength presented in this chapter will allow more realistic 
estimation of the effectiveness of engineering and non-engineering methods used in 
indoor environment for mitigation. Based the limited data presented in this chapter it 
can be observed that more than 105 virus particles can be released by infected person 
during 30 minutes’ collection. In all three samples 1.5 – 2.5×102 viruses were viable, 
or even one order of magnitude higher 2.4 – 3.9×103 if correction from Pan et al. (2016) 
(Figure 3.7) are included. This will have significant impact on evaluation of ventilation 
rates, total air exchange rates and use of upper room ultra violet germicidal irradiation 
in hospitals, health clinics and other densely occupied environments with high risk of 
influenza transmission.  
It is difficult to mitigate the infectious disease spread, since it lies in mismatch 
between detectible symptoms and the onset of infectiousness. Onset of infectiousness 





diagnosed and public health measures like face masks (Milton et al., 2013) can be 
effectively deployed, virus particles exhaled by infected occupant have already been 
polluting indoor environment for several days. This suggests that deploying only non-
engineering control strategies may not be sufficiently effective to mitigate disease 
outbreaks (Cheng and Liao, 2013). Previous studies demonstrated that proper 
ventilation could reduce exposure to simulated expiratory droplets (Cermak and 
Melikov, 2007; Licina et al., 2015; Pantelic et al., 2009, 2015). Although these studies 
showed promising results in occupant exposure reduction, it is still unclear if reduced 
exposure is sufficient to reduce number of secondary cases. In order to evaluate how 
effective different measures are or how effective they need to be to mitigate airborne 
disease spread, knowledge of the source strength represent the starting point. The 
technology and methods described in this study could be used to effectively quantify 
the source strength, and act as a basis for further prevention analysis.   
One limitation of the present study is the inability to perform focus assay analysis 
of the coarse fraction of the aerosol. Further development of coarse fraction collection 
and enabling more advance biological analysis will be discussed in the future work 
section of the dissertation. Aerosolization of B/Lee virus with Collison nebulizer 
caused virus inactivation, another limitation of our study. Even though influenza B is 
less common, it still can cause outbreaks of seasonal flu. It is important to know if our 
G-II can sample the influenza B and preserve the viability efficiency. In our future work 
we will test different methods of aerosolization of B type influenza viruses to perform 





T/I ratios measured in our study refer to the virus after aerosolization took place; 
hence any reduction of virus viability due to the aerosolization method is embedded in 
the result. We used Pan et al. (2016) T/I results to compensate for the losses during 
aerosolization. Besides viability decay due to aerosolization, T/I ratio will vary from 
virus to virus, will depend on the method of virus preparation and probably will have 
person to person variability. 
3.6 Conclusions 
The G-II can be used to effectively collect different strains of influenza. Viability 
of different strains was preserved during the collection process. This suggests that the 
G-II can be successfully used to collect samples from subjects infected with influenza 
without prior knowledge of influenza subtype. During sample collection, the G-II 
should be operated with supersaturation ratio of 2.6 or higher. Viability of collected 
sample can be increased if booth air temperature is 24 ℃ or higher and RH of booth 
air is 65% or higher. These settings are recommended during sample collection. 
Temperature of coolant should be recorded during the sampling. Analysis presented in 
this study showed that between 16% and 41% of the virus captured on the Teflon 
substrate could be recovered via RT-PCR analysis. Based on the three samples 
collected from influenza-infected subjects we showed how the quantity of virus 






CHAPTER 4: ROLE OF TIDAL BREATH, COUGH, AND SNEEZE IN 
GENERATION OF INFECTIOUS AEROSOLS BY 142 CASES OF 
COMMUNITY ACQUIRED INFLUENZA 
4.1 Abstract 
Understanding of the relative importance of the modes of influenza virus 
transmission is key to the design of effective public health intervention strategies. 
Previous reports characterized influenza aerosols from small numbers of subjects; none 
have characterized large numbers or examined the role of cough. 
We screened volunteers with influenza like illess (ILI) and recruited those meeting 
the following criteria: (1) positive rapid test, or (2) T >37.8 °C plus cough or sore throat, 
and (3) within the first 3 days of symptom onset. We collected NP swabs and exhaled 
breath samples from each subject on enrollment and for up to 3 consecutive days. Each 
NP swab and fine (< 5 μm) aerosol sample was assayed by culture passage and 
fluorescent focus assay (FFU) on MDCK cells. Influenza RNA copies in all samples 
were quantified by RT-qPCR. 
We screened 355 individuals and enrolled 177 (87 females and 90 males, mean 
age 23) for 178 illness episodes. Of the 178 episodes, we confirmed influenza infection 
in 156 cases, and identified 89 influenza A infections, 50 influenza B infections and 3 
dual infections.  
Among the confirmed cases: We obtained valid culture results (passage and/or 





and 52 (39%) of fine aerosol samples were positive. RT-qPCR was positive in 88 of 
218 (40%) coarse and 166 of 218 (83%) fine 30-min aerosol samples. We observed 
significant correlations of cough with viral RNA copies in coarse (p = 0.0083) and fine 
(p< 0.0001); some cases without cough shed fine aerosols with up to 2.3*105 RNA 
copies and 140 FFU/ 30-min. 
The presence of culturable influenza virus in nearly half of the fine aerosol samples 
demonstrates that influenza cases shed infectious virus as well as RNA into airborne 
droplets and contributes to the biological plausibility and likely importance of airborne 
influenza transmission. However, cough was not a strong predictor of infectious aerosol 
generation suggesting an important role for other mechanisms of aerosol generation. 
4.2 Introduction 
Influenza remains a global threat; The World Health Organization (WHO) 
estimated that annual epidemics account for an estimated 3 to 5 million cases of severe 
illness and 250,000 to 500,000 deaths each year worldwide (Elovainio, 2008). Non-
pharmaceutical interventions have been employed to control and reduce the impact of 
influenza epidemics and pandemics. However, to design effective non-pharmaceutical 
interventions, it is necessary to accurately define the contribution of each route of 
transmission (Atkinson and Wein, 2008) and implement interventions that impede the 
important routes.  
Influenza is thought to have three main routes of transmission: (1) by direct and 
indirect contact with secretions, (2) by large droplet spray (droplets >5 to 10 µm in 





transmission with increasing probability for smaller droplets that can remain suspended 
in the air for minutes to hours (Alford et al., 1966; Atkinson and Wein, 2008; Duguid, 
1946; Gralton et al., 2011; Tellier, 2006, 2009). Due to limitations inherent to sampling 
virus shedding via various routes from infected individuals and the difficulty of 
distinguishing routes of transmission in observational studies, the quantitative 
dynamics and relative contributions of each route are not well understood (Atkinson 
and Wein, 2008; Tellier, 2009). Yet, accurate quantitation is needed to develop models 
to predict the impact of non-pharmaceutical interventions. Recent reports have shown 
that, at least with forced coughs or forced vital capacity maneuvers, infectious influenza 
virus can be recovered from exhaled aerosols (Lindsley et al., 2010, 2016; Milton et 
al., 2013). These studies do not provide sufficient data to quantify the extent of aerosol 
shedding during natural breathing or identify the contributions of spontaneous coughs 
and sneezes commonly thought to be the most important mechanism for viral shedding. 
This chapter addressed these key knowledge gaps by characterizing influenza virus in 
exhaled breath from community acquired cases during natural breathing, coughing, and 
sneezing, and assessing the infectivity of naturally occurring influenza aerosols.  
4.3 Methods 
4.3.1 Study Population and Procedures 
We recruited volunteers with acute respiratory illness on the University of 
Maryland-College Park campus (UMD) and surrounding community from December 





and we obtained a signed consent (or assent and parental verbal assent) from volunteers 
who reported fever with a cough or sore throat (Appendix B Figure B1). 
During the initial visit, we administered a brief screening questionnaire, measured 
oral temperature, height, weight, and collected two nasopharyngeal (NP) swabs 
[Copan, Murrieta, CA] for each volunteer screened. One swab was used to perform 
QuickVue A/B rapid tests for influenza (except when results of a rapid test performed 
by medical provider were available). The second swab was used for viral culture and 
PCR for those meeting enrollment criteria and for PCR in a random sample of 24 of 
those not enrolled. Volunteers were enrolled in exhaled breath collection if they met 
the following criteria: (1) positive QuickVue rapid test, or oral temperature ≥ 37.8 °C 
plus cough or sore throat, and (2) presented within the first 3 days of symptom onset.  
The screening questionnaire asked about sex, antipyretic use, vaccination status, 
and current symptoms rated on a 4-point scale [none, mild, moderate, severe]. We 
defined symptoms as upper respiratory (runny nose, stuffy nose, sneezing, sore throat, 
and earache), lower respiratory (chest tightness, shortness of breath, and cough), and 
systemic (malaise, headache, muscle/joint ache, fever/sweats/chills, and swollen lymph 
nodes). Participants who met eligibility criteria for exhaled breath testing were asked, 
at the time of enrollment, to rate the worst symptoms during the illness thus far, and 
about respiratory symptoms, use of steroid medications, and medical and smoking 
history.  
We collected exhaled breath for 30 min while the participant was seated with their 





bioaerosol sampler as previously described (Fabian et al., 2008; McDevitt et al., 2013; 
Milton et al., 2013) (Appendix B Figure B3). The cone shaped inlet act as a capture 
hood with a 130 L/min flow allowed participants to breathe, talk, cough, and sneeze 
naturally throughout sample collection while maintaining >100% collection efficiency 
for exhaled and coughed droplets ≤ 100 µm. Subjects were asked to breathe normally 
and to recite the alphabet once at 5, 15, and 25 min). We collected “coarse” (>5 µm) 
aerosol droplets by impaction on a Teflon® surface and “fine” droplets (≤5 µm and 
>0.05 µm) by condensation growth and impaction on a steel surface constantly rinsed 
into a buffer containing (phosphate buffered saline with 0.1% bovine serum albumin) 
liquid reservoir. Audible spontaneous coughs and sneezes during breath collection 
were counted by direct observation in real-time (59) or by playback of digital 
recordings (159).  
Participants enrolled prior to the third day after symptom onset were asked to come 
in for up to three consecutive daily follow-up visits (Figure B1) with repeat 
questionnaire, NP swab and exhaled breath collections. Final analyses included only 
visits for enrolled cases occurring on days 1 to 3 post onset with complete data on cough 
and sneeze, symptoms, PCR results for swab and aerosol samples. 
4.3.2 Laboratory Tests 
NP swabs were eluted in 1 mL elution medium, and Teflon® impactors were 
scrubbed with a nylon swab saturated with phosphate buffered saline supplemented 





PBS/0.1% BSA.  Fine aerosol samples were concentrated to 1 mL using centrifugal 
ultrafiltration.    
RNA was extracted from NP swab, fine and course aerosol samples, and whole-
virion standards using, viral RNA was quantified by one-step real-time RT-PCR. 
Standard curves were calibrated for virus copy number using plasmids containing a 
cDNA copy of the RT-qPCR target amplicon. For influenza A, the limit of detection 
(LOD) of the RT-qPCR assay was 20 copies per reaction and the limit of quantification 
(LOQ) was 80 copies per reaction. For influenza B the LOD was 20 copies per reaction, 
and the LOQ was 360 copies per reaction. After accounting for dilution factors, the 
LOQs for NP swabs were 8,000 and 36,000 copies and for aerosol samples were 2000 
and 9,000 copies for influenza A and B respectively.  
Virus culture on Madin-Darby canine kidney (MDCK) cells was used to detect 
infectious virus in NP swab and fine aerosol samples. Infectious virus was not 
measured on the Teflon® impactor samples, since the method of collection is expected 
to have affected infectivity of those samples. Infectious influenza virus was quantified 
using an immunofluorescence assay for influenza nucleoprotein, and positive cells 
were counted by fluorescence microscopy. Details of laboratory methods can be found 
in the Appendix B.  
4.3.3 Statistical Analysis 
We entered and cleaned data using locally hosted REDCap data capture tools 
(Harris et al., 2009) and performed data management and analyses in R (version 3.2.3 





and produced graphics with Prism Software (PRISM software version 7.0; GraphPad). 
We used Spearman correlation, generalized linear models (SAS Proc GENMOD), and 
Tobit regression (Twisk and Rijmen, 2009) with nested random effects of subject and 
sample ID in SAS (Proc NLMIXED) to analyze FFU counts and RNA copy numbers 
and compute geometric mean virus concentrations. Tobit regression accounted for 
uncertainty and censoring of the observations by the limit of quantification. We 
included all independent variables with unadjusted p < 0.10 in initial adjusted models 
and selected final models using the Akaike information criterion. 
4.4 Results  
We screened 355 volunteers with acute respiratory illness; 178 met enrollment 
criteria and provided 278 visits for sample collection. We confirmed influenza infection 
in 156 of the enrolled using RT-qPCR; 152 had at least one positive NP swab and 4 
(3%) were confirmed on the basis of positive aerosol samples. NP swab analysis was 
positive for 8 (33%) of 24 randomly selected volunteers who did not meet enrollment 
criteria; thus, sensitivity and specificity of our enrollment criteria, during the 2012-13 
season, were 57% and 73% respectively. We excluded from analysis 8 visits made on 
the day of symptom onset, 10 made >3 days after onset, 7 with missing data for cough, 
and 3 visits with incomplete RT-qPCR data resulting in complete data on RNA copies, 
cough, and symptoms for 218 visits by 142 cases including 89 influenza A, 50 influenza 





Our study population (Table 4.1) consisted mostly of young adults with high 
asthma prevalence, normal body mass index (BMI), and a low influenza vaccination 
rate. We observed at least one cough during 195 (89%) and at least one sneeze during 
11 (5%) of the 218 visits. Cough varied considerably from 5/30 min at the 25th 
percentile to 39/30 min at the 75th.  Most volunteers rated their upper respiratory 
symptoms as mild to moderate, systemic symptoms as moderate to severe and lower 
respiratory symptoms as mild (Appendix B Figure B6). 
Table 4.1. Characteristics of Study Participants 
 Screened Only Enrolled Complete Data 
N participants  177 178 142 
Breath collection visits – 278 218 
Male (%) 89 (50) 91 (51) 69 (49) 
Flu shot this season (%) 53 (30) 42 (24) 31 (22) 
Asthma, self reported (%) – 38 (21) 30 (21) 
Smoker, current (%) – 30 (17) 21 (15) 
Anti-viral medication last 24 hr (%) 2 11 (6) 7 (5) 
Age (IQR)* 20 (19-22) 21 (19-22) 20 (19 – 21) 
BMI (IQR) 23.6 (21.3-26.2) 23.2 (21.0-25.7)  22.7 (20.9-25.5) 
Body temperature measured onsite 36.9 (36.8-37.1) 37.2(36.9-37.7) 37.2(36.9-37.6) 
Median Coughs/30 minutes (IQR)† – 17 (6-39) 18 (5 – 39) 
Median Sneezes/30 minutes (IQR) – 0 (0-0) 0 (0 – 0) 
Median Upper respiratory 
symptoms (IQR)‡ 7 (4-9) 6 (5-8) 
7 (5 – 8) 
Median Lower respiratory 
symptoms (IQR) 2 (1-4) 3 (2-5) 
3 (2 – 6) 
Median Systemic symptoms (IQR) 6 (3-9) 8 (5-11) 8 (5 – 11) 
* IQR denotes innerquartile range.  
† Cough, sneeze, and symptom scores are reported per visit 
‡ Twelve symptoms were rated from 0 to 3 with maximum possible composite score of 15 for upper 






Infectious virus was recovered from 52 (39%) of 134 fine aerosol samples and 150 
(89%) of 169 NP swabs from which we obtained valid cultures. Quantitative cultures 
A          B 
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Figure 4.1. Viral shedding in swabs and aerosol samples and the effect of cough: A) infectious influenza virus in 
NP swabs and fine aerosols; B) RNA copies in NP swabs, coarse, and fine aerosols; C) RNA copies stratified by 
observed number of coughs in NP swabs, D) coarse aerosols, and E) in fine aerosols. NP = nasopharyngeal swab, 
Coarse Aerosol = droplets >5 µm and Fine Aerosol = droplets ≤ 5µm in aerodynamic diameter.  
 










NP swab  211/218 (2.2×109, 8.3×107–1.5×1010) 
98/159  
(2.5×103, 5×105) 150/169 (89) 
Coarse aerosol 88/218 (6.0×103, 1.9×103–5.0×104) – – 
Fine aerosol  166/218 (2.2×104, 4.2×103–2.0×105) 
41/136  
(37, 1×103) 52/134 (39) 







were positive for 98 (62%) of 159 NP swabs with geometric mean of positive samples 
2.5x103 (95%Cl 1.3×103 to 4.7×103); 41 (30%) of 136 fine aerosol quantitative cultures 
with GM 37 (95%Cl 23.4 to 60.0) FFU in 30-min aerosol samples (Table 4.2 and Figure 
4.1A). Using Tobit analysis to adjust the estimate of the geometric mean for samples 
below the limit of detection we obtain GM 60.6 (95% CI 22.7 to 1.6×102) and GM 1.6 
(95% CI 0.7 to 3.5) for NP swabs and fine aerosols respectively.  
Influenza virus RNA was detected in 211 (95%) of the NP swabs, 88 (40%) of the 
coarse, and 166 (76%) of the fine aerosol samples from the 218 visits included in the 
final analysis. For the positive samples, we observed geometric mean viral RNA 
content of NP swabs was 8.2×108 (95%Cl 4.8×108 to 1.4×109), that of coarse aerosols 
1.2×104 (95% CI 7.1×103 to 2.1×104) and for fine aerosols 3.8×104 (95% CI 2.5×104 
to 5.7×104), Figure 4.1B. The adjusted geometric means for coarse aerosols were 
6.0×102 (95% CI 3.0×102 to 1.2×103) and for fine aerosols 1.2×104 (95% CI 7.0×103 
to 1.9×104).  
We observed a moderately strong correlation between the number of viral RNA 
copies and quantitative culture (r = 0.58) for NP swabs and a weak but significant 
correlation (r = 0.34) for fine aerosols (Figure 4.2 A, B). We observed 16 fold (95% CI 
10 to 27) greater viral content in fine compared with coarse aerosols. Cough frequency 
was not associated with viral RNA in NP swabs (r = 0.02). But, cough was associated 
viral RNA copies in coarse (r = 0.24) and fine (r = 0.45) aerosols (Figures 4.2 C-E). 





of cases who never coughed RNA copies ranged from <LOD to 3.7×105 (adjusted GM 
1.5×103, 95% CI 4.2×102 to 5.3×103) and from 0 to 1.3×102 FFU.   
The detailed Tobit models are shown in Table 4.3 for NP, coarse and fine 
respectively. The detailed Tobit model SAS codes were attached in Appendix C. In 
single predictor models, NP fraction RNA virus copy number is neither associated with 
the fine (p = 0.16) fraction RNA copies nor the coarse (p = 0.48) fraction. Cough 
number is associated significantly with coarse (p = 0.0083) and fine (p< 0.0001) 
fraction RNA virus copy numbers. Reported feverishness is associated with a non-
significant trend toward higher virus copy numbers in NP (p = 0.11) and fine (p = 
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Figure 4.2. Correlation of Influenza Virus Load with Cough: A-B) Numbers of culturable influenza virus and 





0.29) fractions, and toward lower virus copy number in coarse fraction sample (p = 
0.60). Among the 31 subjects who received the current year vaccine, 22 of them also 
got the previous year’s vaccine. Vaccination in both years was associated with a 
significant trend toward higher copy numbers in fine (p = 0.04), and is neither 
associated with coarse (p = 0.89) nor NP fractions (p = 0.80). There were too few cases 
with anti-flu medication in our data collection to analyze. Smoking is not a significant 
predictor for any of the three sample types. Virus copy number in fine samples declined 
with time since onset of symptoms. On day 2 the amount of virus observed by RT-
qPCR in fine fraction aerosol was 44% (95% CI 18% to 105%) of that observed on day 
one. Similar to day 2, observed virus on day 3 was 20% (95% CI 8% to 52%) the 
number of RNA copies detected on day one. This trend in RNA copies detected on day 
post symptom onset in fine aerosols was similarly observed for the coarse aerosol 
fraction. Compared with day 1, RNA copies quantified in coarse aerosols on days 2 
and 3 post symptom onset were 34% (95% CI 10% to 112%) and 29% (95% CI 8.1% 
to 103%) respectively. NP swab viral content was not associated with day post onset.  
The influenza infection type, either flu A or B, is associated with a non-significant 
trend toward lower virus copy number in NP (p = 0.62) coarse (p = 0.84) and fine (p = 
0.23) samples. Upper, lower and systemic symptoms are significant predictors for NP 
swab viral content. An increase from 25th to 75th percentile in upper symptom score 
produced a 3.4-fold increase in RT-qPCR quantified copy number in the NP swab. 
Lower and systemic symptom scores increase from 25th to 75th percentile produced 
3.2 and 5.3-fold increase in RNA copy number respectively. Symptoms are not 





trend toward higher virus copy number in coarse (p = 0.08) and fine (p = 0.06) samples. 
An increase from 25th to 75th percentile in BMI produced around 2-fold increase in both 
coarse and fine fraction aerosols.  
In multiple predictor models (Table 4.3), NP swab viral content is significantly 
associated with age and upper respiratory symptom score. With a 25th to 75th percentile 
change in upper respiratory symptom score producing a 3.3-fold increase, and subject 
who are older will shed less RNA copies in NP swab. In the full model, coarse and fine 
aerosol viral contents are significantly associated with BMI, cough and day post 
symptom onset, with similar trends observed in the single predictor model. Vaccination 
of both seasons is a significant predictor in fine aerosol, with people who were vaccine 
in two seasons in a row will shed about 4-fold more viral content in fine aerosol. The 
interaction between gender and cough is also a significant predictor in the fine aerosol 
full regression model, with males showing almost a 4-fold increase from 25th to 75th 






Table 4.3 Predictors of Viral Shedding 
Parameter NP Swab Coarse Aerosol Fine Aerosol 







(0.90 – 1.2) - 
0.99 
(0.88 – 1.1) - 
Male  0.34 (0.14 – 2.5) - 
1.7 
(0.52 – 5.6) - 
2.4* 
(0.88 – 6.5) - 
Asthma 3.8 (0.63 –22.9) - 
1.38 
(0.32 – 6.04) - 
2.6 
(0.77 –8.95) - 
Smoker  2.3 (0.30 –18.2) - 
0.48 
(0.09 –2.7) - 
1.5 
(0.36 – 6.1) - 
BMI 1.3 (0.58 – 2.7) - 
1.9* 




(0.98 – 2.9) 
     1.7† 




(0.22 – 7.6) - 
1.4 
(0.34 –5.9) - 
2.8* 
(0.85 –9.3)      - 
Previous year 
influenza vaccination  
1.55 
(0.45 – 5.5) - 
0.71 
(0.15 – 3.3) - 
2.3 
(0.79 - 6.6)      - 




(0.10 – 5.7) - 
1.13 
(0.22 – 5.7) - 
2.1‡ 
(1.3 –3.2) 
    3.9‡ 
(1.2 –12.7) 
Antiviral medication  1.1 (0.03 –33.9) - 
0.64 
(0.04 –11.5) - 
1.04 
(0.09 –12.0) - 
Influenza A 0.67 (0.13 – 3.3) - 
1.0 
(0.18 – 5.5) - 
0.44 
(0.13 –1.5) - 
Log (NP Swab) - - 1.3 (0.91 – 1.82) - 
1.2 
(0.76 –1.78) - 
Day 2 post onset 2.13 (0.48 –9.5) - 
0.34* 
















Fever (T≥ 37.8 
measured at visit) 
3.6 
(0.76 –17.2) - 
0.70 
(0.19 –2.7) - 
1.7 
(0.64 – 4.5) - 
Number of coughs 1.3 (0.65 – 2.8) - 
2.1‡  












(1.61 – 6.7) 
0.76 
(0.44– 1.3) - 
0.88 




(0.96 – 10.8) 
1.3 
(0.32 – 5.1) 
0.94 
(0.36 – 2.5) - 
1.9 
(0.86 – 4.1) - 
Systemic symptoms 5.3
‡ 
(1.6 – 17.7) 
1.2 
(0.58 – 9.3) 
0.86 
(0.33 –2.3) - 
1.8 
(0.82 – 3.7) - 
Male × Number of 
Coughs - - - - - 
3.9§ 
(1.8 – 8.4) 
* Effect estimates are shown as the ratio of male to female, Day 2 or Day 3 to Day 1, type A to B, or fold increase for an 
inner quartile range (IQR) change in age, the number of coughs, symptom reports, or BMI, or ratio of male number of 
coughs to female coughs over the IQR. 
* p< 0.10, † p< 0.05, ‡ p< 0.01, § p< 0.001, ¶ p< 0.0001 from Tobit regression models with random effect of subject and 
sample within subject. Adjusted models were selected using the Akaike information criterion from initial models with all 






We have successfully cultured 52 aerosol samples. The presence of culturable 
influenza virus in nearly 40% of the fine aerosol samples demonstrates that influenza 
cases shed infectious virus as well as RNA into airborne droplets and contributes to the 
biological plausibility and likely importance of airborne influenza transmission. 
Analysis of exhaled breath particles from the naturally influenza infected cases 
indicates that the fine particle fraction of exhaled breath contains more RNA copies 
than the coarse particle fraction suggests that fine particle aerosols contribute to 
transmission of influenza. These results have implications on the prevention of 
influenza virus transmission. 
We found that flu cases do not sneeze, despite having just undergone two NP swab 
collections (a procedure that generally makes one want to sneeze) and subsequent 30-
minute observation. People with flu do cough (Roy and Milton, 2004; Tang and Settles, 
2008; Yang et al., 2007), and taken together with the sneeze data could suggest that 
sneezing is more characteristic of other respiratory infections but not flu (Appendix B 
Figure B4). Cough did have an impact on how much virus observed cases were 
shedding (Lindsley et al., 2010), but without cough, cases still shed large quantities of 
culturable, contagious virus into fine aerosols, which suggests that other aerosol 
generating mechanisms are going on in the lung. The aerosol generation without cough 
may probably due to airway closure and opening (Almstrand et al., 2010). This has 
been extensively studied in the pulmonary literature in recent years in studies 
attempting to identify early biomarkers of pulmonary pathology in exhaled breath 





When we look at predictors of viral content in NP swab specimens, we saw upper 
respiratory symptom score as a significant one, which supports the notion that 
symptomatic viral nasopharyngeal infections are indicative of upper respiratory 
infection, as opposed to lower respiratory or overall symptoms. The amount of viral 
content in the NP swab does not predict how much we observed in either coarse or fine 
aerosols suggesting that these are two are different phenomena and viral content in 
aerosols is probably representing infection of the lower respiratory tract. Another 
explanation is that there is not enough turbulence during breathing to generate aerosols 
in the upper respiratory tract, and most of the aerosols are generated from the lower 
airway in which we did not see a correlation between NP swab and aerosol samples 
driven by different symptoms (Gralton et al., 2013; Shinya et al., 2006). There was no 
difference in viral shedding between female and male when they don’t cough, however 
among cases who coughed, males generated more aerosols than females. This may be 
due to a larger lung capacity in male volunteers, since the sex effect of our data is on 
total virus output, not corrected for lung size of individual and tidal breath of the case. 
The influence of height and pulmonary function may have resulted from the sex 
difference (Kastelik et al., 2002). If the data were corrected in that way, the results 
might be slightly different, with significant effect of sex resolving to non-significance.  
People who received both current and previous year vaccination shed more viral 
content in fine aerosol based on our Tobit model results. It could possibly be due to the 
subjects having received mismatched vaccine for the 2012-2013 flu season. The current 
year vaccination is a significant predictor only in flu A infection, and CDC reported 





than the 67% of flu B (Centers for Disease Control and Prevention, 2013). The majority 
of the group received vaccine two seasons in a row, which may have reduced their 
opportunity to build naturally acquired immunity (immunity from having the disease 
itself), which is considered much stronger than the immunity provided by vaccine 
(Centers for Disease Control and Prevention, 2013). When they are exposed to 
influenza viruses not included in the vaccine, their immunity is not strong enough and 
they may have a higher chance of getting sick, leading to a more severe response 
towards the infections.   
Not all cases with confirmed influenza infection had symptomatic illness, and it 
was hard to identify the transmissivity of these people. Based on our results, people 
without severe symptoms can still shed a large quantity of virus into the air. Cases who 
did not complain of any upper respiratory symptoms still shed 104 RNA copies. Cases 
who did not have any systemic symptoms can shed up to 107 RNA copies for fine 
fraction aerosols. The asymptomatic fraction of infected individuals requires further 






CHAPTER 5:  CLIMATE EFFECTS ON INFECTIOUS INFLUENZA 
VIRUS IN HUMAN EXHALED BREATH 
5.1 Abstract 
Influenza transmission is often associated with climatic factors. The survival of 
influenza virus virions within the particles is affected by environmental factors such as 
temperature and humidity. The rate of evaporation of particles, which affects the final 
particle size distribution also highly influenced by the climate factors. In this study, we 
screened volunteers from three locations, University of Massachusetts (UML), 
University of Hong Kong (UHK) and National University of Singapore (NUS). These 
three locations represent three types of climates, temperate, subtropical and tropical. 
The volunteers that are invited for the study from all three sites have either a positive 
test with the rapid test or reported symptoms and who had a body temperature of ≥
37.8 ℃. All three locations measured exhaled influenza viral particle copy number RT-
PCR in two particle size fractions, ≥5 µm (coarse) and <5 µm (fine).  In all three 
locations, the fine particles had more viral copy number than in the coarse fraction 
which have suggested an important role for aerosols in seasonal influenza transmission. 
NUS and UHK have relatively higher virus copies reading from RT-PCR for the 
collected exhaled breath samples compared to UML, which suggests airborne 
transmission route cannot be negligible in tropical regions even with less variability in 





5.2 Introduction  
Influenza respiratory infection still remains as a public health importance with 
substantial burden of morbidity and mortality (Belser et al., 2010; Elovainio, 2008). 
The ability of influenza viruses to spread through susceptible populations to cause 
annual epidemics and occasional pandemics is well documented. Whether the infection 
leads to disease depends on various factors. Once the infection occurs, the host will 
have the ability to release the pathogen within respiratory secretions into the air during 
breathing, coughing, sneezing or talking. There are three primary modes of 
transmission: droplet, contact and airborne. Droplet and contact modes involve large 
particles (>100 µm). The large respiratory droplets can travel only for a short distance 
before landing on the ground.  Airborne transmission involves small aerosols with size 
< 10 µm that will stay and remain suspended in air for a relatively longer period of time 
and more likely to pass into the lower respiratory tract.  
The transmissibility is highly influenced by the exposure environmental 
conditions, such as, humidity, temperature, seasonality, settings (indoor or outdoor), 
solar irradiation and air exchange in which the pathogen and host meet (Pica and 
Bouvier, 2012). The seasonality of influenza epidemics has been confounded by climate 
factors such as temperature and humidity. These factors strongly affect the production 
of influenza-laden particles and also the viability of the virus particles, which is linked 
to risk of infection. It is believed that airborne route is dominant in the temperate 
climate region due to distinct seasonality. The relative lack of seasonality in tropical 
regions with less variability in temperature and humidity are suggested to be dominant 





There have been many published papers with a lot of experimental work in the 
literature to study the effect of environmental parameters on the survival of airborne 
influenza virus. To date, there is still debate over how the environmental impacts 
influence the infected host viral shedding. Lowen et al., 2007 used guinea pigs to show 
that the infected hosts shed significantly higher quantities of viral particles when 
exposed to lower ambient temperature than those were exposed to higher temperature. 
There have not been any human subjects studies on testing the climate effects on the 
naturally infected cases. 
Our study fits this knowledge gap by screening naturally influenza infected 
volunteers from three locations, University of Massachusetts Lowell (UML), 
University of Hong Kong (UHK) and National University of Singapore (NUS). These 
three locations represent three types of climates, temperate, subtropical and tropical. 
The effects of outside environmental parameters on human viral shedding are discussed 
in this chapter.  
5.3 Methods 
5.3.1 Subject Recruitment 
In the study that was done at the UML, the volunteers were mostly students and 
staff who were recruited with influenza-like illness from the Lowell, MA community, 
beginning January 29 and ending March 12, 2009. The study protocol was approved 
by the Institutional Review Boards and the detailed recruiting protocol can be found in 
Milton, et al., 2013. A nasopharyngeal specimen (NP swab) using a flocked swab was 





a body temperature≥37.8 °C and volunteers without fever who provided a NP swab 
positive for influenza by QuikVue influenza A/B were invited to provide exhaled 
breath samples, answer a questionnaire, and provide a second NP swab for analysis by 
real-time reverse transcription polymerase chain reaction (RT-PCR).  
UHK conducted their study in a local outpatient clinic in a private hospital. The 
volunteers that were invited to the study were at least 11 years old and with at least two 
symptoms of acute respiratory illness (ARI) within 3 days of the onset of symptoms. 
The study was explained to the volunteers before they gave the signed paper consent. 
If the volunteer was between 11-18 years old, a signed consent form from both the 
subject and his guardian was obtained. The study protocol was also approved by the 
Institutional Review Boards. After obtaining the consent, a 5-minute questionnaire was 
administered by the research staff. A nasopharyngeal specimen using a flocked swab 
was collected to test for whether the subject is influenza A/B positive by the Quidel 
Sofia influenza A+B rapid test and temperature was taken with a Tympanic 
thermometer (Cat #TH-809, OTO Bodycare, Hong Kong). If the rapid test proved to 
be positive, a separate nasal swab and throat swab was obtained for further PCR testing 
and then subjected to exhaled breath collection for 30 minutes.  
NUS performed the experiments in a similar way like UHK and UML. Patients 
were recruited at the University Health Centre (UHC) at the National University of 
Singapore (NUS). When patients registered at the clinic, those with 2 or more of any 
of the ARI symptoms were recruited for the study. The patients were only considered 





screening for influenza cases. A nasopharyngeal specimen was taken to run the rapid 
test (quick NaviFlu). If the rapid test showed positive, the patient was asked to the 
follow up G-II collection. If patients had a fever, even if the rapid test is negative they 
were still asked to participate in exhaled breath sampling. If the patient did not have 
fever and two of the other symptoms, they were not invited to the follow up study.  
5.3.2 Exhaled Breath Collection 
The exhaled breath was collected with the subject seated in front of the inlet of 
novel exhaled breath aerosol collector named G-II. The device is capable of providing 
information of the total and viable virus counts in the exhaled breath. The detail 
description can be found in McDevitt et al. (2013) and is also discussed briefly in the 
Milton et al. (2013). The G-II inlet was cone shaped so that the subject’s face was 
situated inside the large end of an open cone with intake air (125 L/min) drawn 
continuously around the subject and into the sampler. The subject could breathe 
normally while sitting awake in the cone. The cone captured the exhaled breath with 
minimal leakage even with redirection of the flow. Air flowed through a Teflon surface 
conventional slit impactor that collects ≥5 µm particles.  After that, all the remaining 
fine particles were grown bigger by condensation and were captured by a 1.0 µm slit 
impactor and drained into a buffer containing liquid in the bottom of the reservoir. 
Concentrated buffer (phosphate buffered saline with 0.1% bovine serum albumin) was 
constantly pumped into the reservoir to preserve the virus viability. The collected 





5.3.3 Sample Analysis 
For all three locations, the Teflon impactor surface was scraped with a flocked 
swab after collection and eluted in Dulbecco's phosphate buffered saline with calcium 
and magnesium with 0.1% bovine serum albumin (DPBS++BSA) for 1 minute with 
vortexing. The resulting sample was stored at −80 °C. The fine particle fraction 
collected in DPBS++BSA buffer (100 to 150 ml volume) was maintained at 4 °C and 
concentrated by ultrafiltration to a volume of approximately 400 µl. Following 
ultrafiltration, the filter was washed with 200 µl of DPBS++BSA, and the wash solution 
was combined with the retentate. Samples were stored at −80 °C.  
For UML, quantitative PCR was performed and the limits of detection were 6 and 
11 viral RNA copies per qPCR well for influenza A and B respectively. The detailed 
sample analysis for the UML was described in the Milton et al. (2013). For UHK and 
NUS, sample analysis was similar. 
From UHK, 250 µl of sampled specimen was added to 2 ml lysis buffer provided 
by the manufacturer for nucleic acid extraction. The specimen was incubated for 10 
minutes at room temperature to ensure complete lysis for the release nucleic acids. The 
lysate was mixed with 100 µl magnetic silica and preceded to automatic extraction by 
the NucliSENS® easyMAG®. 55 µl of RNase-free elution buffer was used for the 
recovery of nucleic acid. The extracted nucleic acids were kept frozen at -80oC until 
processing. If the specimen result was outside the upper limit of the expected range, 





Since UHK brought the sample to 2 ml, extracted 250 µl of 2 ml, and then eluted 
to 55 µl, then used 5 µl of that for PCR, the dilution factor is 88. So the limit of detection 
for PCR is 880 virus copies /sample (highest detection limit among three locations). 
Two samples of UHK data were analyzed at the University of Maryland (UMD) 
laboratory. The UHK sample was 2 ml original, and UMD extracted 200 µl of the 2 ml 
sample. The sample was then eluted to 50 µl, and 10 µl was used for PCR, and the 
dilution factor is 50. The limit of detection is 250 copies/sample. 
In NUS, for NP swab samples, the original volume was 1.2 ml. 200 µl from the 
original volume was used for RNA extraction and the sample was eluted in 50 µl, then 
10 µl from this 50 µl was used for qRT-PCR. Therefore, amount of viral copies in the 
original sample has a dilution factor of 30. For fine and coarse particles, the original 
volume was 1 ml; 200 µl from the original volume was used for RNA extraction and 
then eluted in 50 µl, 10 µl from this 50 µl was used for qRT-PCR. Therefore, the 
dilution factor is 25. The detection limit is 150 virus copies/ sample for NP samples 
and 125 for condensation samples. 
5.3.4 Statistical Analysis 
The data analysis was performed in both R and SAS. These two software systems 
are mostly used in epidemiology studies for data analysis and graphics. ANOVA is 
normally used to perform the comparison among multiple groups, but since the data do 
not follow a normal distribution, the Kruskal-Wallis test was used, which can be 
applied when we cannot make the assumption if the groups follow a Gaussian 





NP particle virus copy counts to see the difference among three locations. Following 
with the K-W test, a post-hoc test (a priori statistical methods) is used to confirm the 
result.  
The Chi-square test is used to see if the difference in limit of detection affects the 
comparison of data among all three locations. To test the effect of other influencing 
factors such as medical history, race, and age, the Tobit model was performed. The 
Tobit model analyzed log copy number with a random effect to account for variability 
among different climates. We also used Spearman’s correlation coefficient to examine 
the relationship between the viral load in the nasopharyngeal swab and aerosol 
fractions. 
5.4 Results 
At all three locations, we picked the subjects with a positive nasal or 
nasopharyngeal specimen PCR data. The data that were excluded in this study were 
either with a negative swab RT-PCR data or due to laboratory error in sample 
processing. In UHK, 7 subjects with complete data were picked, 31 subjects from NUS 
and 37 subjects from UML. Exhaled breath samples were obtained for all the selected 
subjects. Table 5.1 shows the sex, symptoms and influenza virus type for all the three 
locations, and Table 5.2 shows descriptive statistics for age, swabs and exhaled aerosol 





 Among all the samples with positive swab data, 57% (4 of 7) of fine particle 
samples from UHK had detectable virus copies from PCR, 42% (13 of 31) of fine 
particle samples from NUS, and 92% (34 of 37) of fine particles samples from UML. 
For the coarse particle samples, UHK showed 29% (2 of 7) of detected virus copies 
from PCR, NUS showed 29% (9 of 31), and UML showed 43% (16 of 37) detected 
virus copies. Combing the coarse and fine fractions, the detected RNA virus copies 
were above 50% of the total samples, which demonstrates the potential importance of 
the airborne particles transmission route.   
Table 5.1. Volunteer's sex, symptoms, temperature, and influenza virus type for all three 
locations 
  
UHK NUS UML 
N Percent N Percent N Percent 
Number of subjects with 
complete data 7 100 31 100 37 100 
Male 3 43 20 65 30 81 
On antiviral medicine 
within past 24 hours 0 0 0 0 0 0 
Asthmatic 1 14 7 23 5 14 
Flu shot this season 0 0 0 0 1 3 
Flu shot previous season 0 0 3 10 12 32 
Smoker 1 14 3 10 9 24 
Breathing difficulty 1 14 3 10 16 43 
Temperature≥37.8 C 2 29 28 90 10 27 






Fine fraction copy numbers were on average 15 times greater than coarse fraction 
copy numbers for UHK, and 14 folds greater for NUS, and 5 folds greater for UML. 
Table 5.3. Chi-square test table for coarse PCR sample results 
Coarse UHK NUS UML Total 
Positive 1 5 2 8 
Negative 6 26 35 67 




Table 5.4. Chi-square test table for fine PCR sample results 
Fine UHK NUS UML Total 
Positive  3 12 6 21 
Negative 4 19 31 55 
Total 7 31 37 75 
 
 
Table 5.2. Descriptive Statistics  
 
Percentiles 
Min 25th Median 75th Max 
UHK 
Age 26 36 42 53 56 
Days since onset 1 1 2 2 3 
Nose swab copy number 1.82×105 2.26×106 5.48×106 1.42×107 9.16×107 
Coarse particle copy 
number  <LOD
*   <LOD  <LOD  1.39×102 4.08×103 
Fine particle copy number  <LOD   <LOD  2.96×102 3.60×103 5.66×104 
NUS 
Age 19 22 23 27 54 
Days since onset 1 1 1 2 3 
Nasopharyngeal swab copy 
number 1.58×10
6 1.70×107 1.36×108 1.03×109 5.52×109 
Coarse particle copy 
number <LOD  <LOD  <LOD  3.62×10
2 3.73×105 
Fine particle copy number <LOD  <LOD  <LOD  9.08×103 5.00×106 
UML 
Age 18 18 19 20 54 
Days since onset 1 1 2 3 5 
Nasopharyngeal swab copy 
number 1.70×10
3 8.30×104 4.20×105 1.80×106 3.40×107 
Coarse particle copy 
number <LOD   <LOD  <LOD  3.7 2.90×10
4 
Fine particle copy number <LOD  1.1 1.10×102 5.60×102 1.30×105 





The coarse and fine fraction copy numbers were correlated (r = 0.60, p< 0.0001) only 
for UML, the other two locations had no such significant correlations. There was no 
significant difference in copy number between influenza A and B for NUS and UML. 
Fine fraction copy numbers were significantly related with the body temperature 
measured at the time of testing in NUS (p=0.003) and UML sites (p = 0.014), but coarse 
fraction copy numbers were only significantly impacted by the feverishness in the NUS 
site (p = 0.002) not UML. UHK site had limited data to do the analysis. Vaccination in 
any prior year was not significantly associated with copy numbers in both fine and 
coarse fractions for all three locations; too few individuals received the current season's 
vaccine to analyze for all three locations.  Self-reported symptoms like breathing 
difficulty and smoking were not associated with significant shifts in aerosol viral load. 
From the boxplots in Figure 5.1, NUS and UHK have relatively higher virus copies 
reading from RT-PCR for all three types of samples compared to UML.   
Since all three locations performed the sample analysis differently with different 
resulting detection limits, the differences in the data sets may mainly result from the 
variance of the limit of detection. In order to generalize the samples data and study if 
A          B     C 
 





the detection limit plays an important role in the data analysis, we picked the highest 
limit detection among all three locations, which is 880 virus copies/sample from UHK 
and did the Chi-square analysis. We categorized the data as above 880 or below 880 
for all three locations. As shown in Table 5.3, the Chi-square test statistic was equal to 
2.14 when degree of freedom (df) is 2 (p = 0.34). Since p > 0.05, the null hypothesis 
cannot be rejected, in which the amount of detectable virus copies in the coarse samples 
are independent of the difference in limit of detection among all three locations. For 
fine particle counts (Table 5.4), Chi-square test statistic was equal to 5.1, with p = 0.08 
and df = 2.  Since p> 0.05, the null hypothesis cannot be rejected, in which the amount 
of detectable virus copies in the fine particles is independent of the difference in limit 
of detection among all three locations.  
From the Kruskal-Wallis rank sum test and post-hoc test, the results appear that 
the viral load of all three samples (NP, fine, coarse) from NUS was significant higher 
than the samples from UML (p<< 0.05). The viral load of aerosol samples from UHK 
appears to have no significant difference with that from either NUS or UML. 
5.5 Discussion 
All three locations measured exhaled influenza viral particle copy number RT-
PCR in two particle size fractions, ≥5 µm (coarse) and < 5 µm (fine).  In all three 
locations, the fine particle fraction had more viral copy number than in the coarse 
fraction, suggesting an important role for aerosols in seasonal influenza transmission.   
Influenza viruses circulate year round in tropical Singapore. In our collected cases 





November−March. The climate in Singapore is characterized as uniform temperatures 
of minimum 23 °C – 26 °C and maximum 31 °C – 34 °C and a relative humidity of 
84% (National Environment Agency, 2016). In temperate countries, seasonal influenza 
epidemics occur during colder months and remain above baseline levels for six to eight 
weeks (S. Monto and G. Webster, 2013). Hong Kong has a subtropical climate and an 
influenza seasonality lying approximately midway (March–June) of the year (Chan et 
al., 1999).  
Singapore surveillance results suggest that influenza outbreaks can persist above 
baseline levels for more than 12 weeks. The influencing factors in determining local 
spread including weather, travel and population dynamics (S. Monto and G. Webster, 
2013). Tropical and subtropical regions with mild winters are subjected to seasonal 
oscillations like rainy seasons in influenza incidence (Alonso et al., 2007). The seasonal 
patterns are generally more pronounced in temperate areas, since there is normally 
more than one period of viral activity occurring in a given year in tropical areas and it 
brings up more complicated mechanisms underlying seasonal patterns observation.  
The results that were presented in this chapter are RT-qPCR measurements of the 
quantity of virus copies in the exhaled breath, not the survivability of the virus particles. 
In general, the airborne survival of the lipid-enveloped influenza virus is affected by 
the local environmental factors. Relative humidity (RH) describes the amount of water 
vapor in the air at a specific temperature at any time which could affect biological 
response (Ehrlich et al., 1970). In Shaman and Kohn, 2009 absolute humidity (AH), 
i.e., the actual water vapor content of air irrespective of temperature has a greater 





lower temperature and lower relative humidity lead to higher viral survival and the 
higher temperatures and higher relative humidity cause lower survival (Lowen et al., 
2007; Shaman and Kohn, 2009; Tellier, 2009). According to the trend, the survivability 
of the influenza virus particles in the tropical countries should be lower than the 
temperate and subtropical countries, which should probably lead to a lower infection 
rate among populations.  
The annual all-cause death rate from seasonal influenza in Singapore has been 
estimated at 14.8/100,000 population per year (Chow et al., 2006); In subtropical Hong 
Kong, death rate from underlying pneumonia and influenza attributable to influenza 
were estimated to be 4.1/100,000 population per year, higher than the rate (3.1/100,000) 
reported in the United States (Chow et al., 2006). It appears that the influenza–related 
excess deaths in Singapore are higher than those in temperate and subtropical countries. 
There is a demonstration of increased airborne transmission indoors which has no 
extreme external environmental factors involved in the virus survival (Rudnick and 
Milton, 2003). The success of aerosol transmission may not solely depend on the 
absolute humidity or temperature effect of the outdoor environment.  
The limited amount of data we have obtained may be difficult to interpret 
conclusively to determine the relationship between climate parameters and the amount 
of infectious particles generated by infected human beings. PCR-based methods cannot 
distinguish between viable and non-viable virus, which is another limitation of our 
study. Many social factors will also be involved with the seasons in different countries. 
People who spend most of their active life indoors in an air-conditioned environment 





environmental factors. On the other hand, the shedding also varies with the individual, 
and the theory of the “super spreader” has been proved in several papers (Glass and 






CHAPTER 6:  MODELING THE EFFECTIVENESS OF 
RESPIRATORY PROTECTIVE DEVICES IN REDUCING 
INFLUENZA OUTBREAK 
6.1 Abstract  
Outbreaks of influenza represent an important health concern worldwide.  In many 
cases vaccines are only partially successful in reducing the infection rate, and 
respiratory protective devices (RPDs) are used as a complementary countermeasure.  
In devising a protection strategy against influenza for a given population, estimates of 
the level of protection afforded by different RPDs are valuable. In this chapter, a risk-
assessment model previously developed in general form was used to estimate the 
effectiveness of different types of protective equipment in reducing the rate of infection 
in an influenza outbreak. It was found that a 50% compliance in donning the device 
resulted in a significant (at least 50% prevalence and 20% cumulative incidence) 
reduction in risk for fitted and unfitted N95 respirators, high-filtration surgical masks, 
and both low-filtration and high-filtration pediatric masks. An 80% compliance rate 
essentially eliminated the influenza outbreak. The results of the present study, as well 
as the application of the model to related influenza scenarios, are potentially useful to 








Influenza remains a global public-health concern; the World Health Organization 
(WHO) estimates show that annual epidemics may cause up to five million severe 
illnesses and 500,000 deaths worldwide (Elovainio, 2008). An increasing number of 
studies suggest that influenza respiratory droplets generated by an expiratory event play 
an important role in transmission (Cowling et al., 2013).  It has been demonstrated in 
the work of Milton et al. (Milton et al., 2013) and Lindsley et al. (Lindsley et al., 2010, 
2015) that aerosol particles released from the human respiratory tract contain 
significant amount of infectious virus. The aerosol fraction that is less than 5 μm in 
diameter (the “respirable fraction”) is of particular concern, because it can remain 
airborne for long periods of time (Gralton et al., 2011, 2013).  The Lindsley et al. study 
(Lindsley et al., 2010) showed that 65% of the influenza viral RNA was contained in 
particles in the respirable size fraction. These particles are small enough to reach the 
lower respiratory tract through inhalation and cause severe infections (Cowling et al., 
2013; Gralton et al., 2011).  
Traditionally, proactive interventions such as seasonal vaccines are used to help 
prevent influenza infection (Elovainio, 2008). A 2014 CDC meta-analysis study 
showed that flu vaccination was responsible for up to 70% reduction in infections 
among all population groups during the 2010-2012 flu seasons (Centers for Disease 
Control and Prevention (CDC), 2013).  This statistic represents a normal season when 
the strain has been predicted accurately a priori. In case of a new strain, a vaccine may 
not be available in time to prevent the virus from becoming a pandemic (Centers for 





Protective Devices (RPD), such as respirators, surgical masks and pediatric masks for 
pediatric population, can provide protection to uninfected individuals, further reducing 
the risk of influenza transmission (Elovainio, 2008).  
To have a better understanding of how influenza spreads, and to evaluate the 
possible influence of different strategies of interventions, many risk assessment models 
in the literature have been implemented (Beauchemin and Handel, 2011; Canini and 
Carrat, 2011; Chen and Liao, 2008; Furuya, 2007; Guo et al., 2015; Keeling and 
Rohani, 2008). Stochastic (probabilistic) and deterministic (compartmental) models are 
the two types of epidemiological modelling techniques (Neyman, 1956). Deterministic 
models have been most widely used for respiratory disease transmission models, in 
which SIR (susceptible-infected-removed), SEIR (Susceptible-Exposed-Infected-
Removed) and Carrier state Models are the most notable ones (Keeling and Rohani, 
2008). The first SIR model was proposed by Kermack and McKendrick (1927) 
(Kermack and McKendrick, 1927) and has been interpreted by Stilianakis and 
Drossinos (SD) (Stilianakis and Drossinos, 2010) to account for the dynamics of 
inhalable respiratory droplets. The SIR model consists of several ordinary differential 
equations (ODEs) coupling the changes in the population of susceptible (S), the 
population of infection cases (I), and the population of recovery to an immune state (R) 
(Stilianakis and Drossinos, 2010). Although a number of papers in the literature have 
addressed how influenza transmission can be prevented using the SIR model (Laguzet 
and Turinici, 2015; Levin et al., 2004; Nichol et al., 2010), major knowledge gaps still 





In particular, tools have not been available to quantify the reduction in risk associated 
with the deployment of different choices of RPDs, for different populations. 
Recently, Myers et al. (Myers et al., 2016) presented a mathematical formulation 
for evaluating the effect of RPDs in reducing the risk of disease transmission by 
inhalable droplets. The model systematically extended previous SIR models to account 
for the change in pathogen generation and transmission introduced by RPDs.  The 
primary purpose of the work was to provide a general mathematical formulation 
applicable to any infection scenario involving inhalable droplets, and to derive a 
“reproduction number” specifying a threshold separating growing and decaying 
infected populations.   
In this chapter, we apply the formulation of Myers et al. (2016)  (Myers et al., 2016) 
to model seasonal influenza outbreak and the effect of RPD intervention, in a closed 
community setting.  We assess the effectiveness of a variety of different RPDs that 
might be used during such an outbreak, including fitted N95 respirators, unfitted N95 
respirators, and facemasks. We evaluate the effect on both the adult and child 
populations.  The models are informed by recently acquired data on the penetration 
factors for the different barriers.  We also performed sensitivity analysis to demonstrate 
how polydispersity of aerosol size distribution, contact rates between susceptible and 





6.3 Methods  
6.3.1 Mathematical formulation 
In the SIR model, susceptible individuals can become infectious, and then 
subsequently recover. Once a person has recovered, we assume that the person will 
remain immune for the rest of that influenza season. The susceptible group (S) has no 
new members added; the only way an individual leaves the S group is by becoming 
infected. The infected population (I) grows due to conversion from the susceptible 
population and decays due to conversion of individuals into the recovered (R) 
population.  In the SIR model modified for RPDs, the susceptible population is divided 
into two groups: the Sr population that deploys RPDs, and the Snr population that does 
not.   For the infected population, a fraction of the population is assumed to deploy 
RPDs, but that population is assumed to convert to a recovered state at the same rate as 
the fraction not deploying RPDs, so it is not necessary to distinguish two populations.   
The equations governing the movement of the population between the different groups, 
due to infection by inhalable droplets and in the presence of RPDs are: 
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Here N is the total population, equal to S + I + R.  D is the total number of droplets, 
and   𝛽𝛽�𝑟𝑟 and 𝛽𝛽�𝑛𝑛𝑟𝑟 are the transmission rates for protected and unprotected susceptible 
populations, respectively.  Both   𝛽𝛽�𝑟𝑟  and 𝛽𝛽�𝑛𝑛𝑟𝑟  are proportional to the breathing rate, 
denoted by B in (Myers et al., 2016).   𝜅𝜅𝑤𝑤  represents the infectious droplet production 
rate, 𝜇𝜇𝐼𝐼   the infection recovery rate, and 1/ν   the droplet removal rate 1/ν.  Equations 
(1a) – (1e) apply for a monodisperse droplet size distribution.  To account for multiple 
droplet sizes, differential equations of the form (1a) – (1e) apply for each size bin.  In 
general, the droplet production rate and removal rate depend upon droplet size.  
In Myers et al. 2016 (Myers et al., 2016), the relationship between the transmission 
rates for the protected and unprotected populations was derived: 
𝛽𝛽�𝑟𝑟  =  𝑇𝑇𝑖𝑖𝑛𝑛 𝛽𝛽�𝑛𝑛𝑟𝑟   (2a) 
Here Tin is the fraction of incoming pathogens transmitted by the RPD when the 
susceptible person breathes in.  The transmission rate in the absence of RPDs can be 
written in terms of more fundamental quantities as (Myers et al., 2016) 
𝛽𝛽�𝑛𝑛𝑟𝑟  =  𝑐𝑐
𝐵𝐵
𝑉𝑉𝑐𝑐𝑐𝑐
𝜏𝜏𝜏𝜏𝜏𝜏𝑁𝑁𝑝𝑝   (2b) 
where c is the contact rate between a susceptible person and an infected person, B 
is the breathing rate, Vcl is the volume of the personal cloud of an infected person, 𝜏𝜏 the 
characteristic breathing time, p the probability of infection by an inhaled pathogen, q 
the inhaled-droplet deposition probability, Np the number of pathogens per droplet.  Of 





The relationship between the droplet production rate in the presence of RPDs, 
𝜅𝜅𝑤𝑤 , and the produced rate in the absence of RPDs, 𝜅𝜅𝑛𝑛𝑟𝑟, was also derived in (Myers et 
al., 2016): 
𝜅𝜅𝑤𝑤 = 𝜅𝜅𝑛𝑛𝑟𝑟[𝑇𝑇𝑜𝑜𝑜𝑜𝑑𝑑 𝑓𝑓𝑖𝑖 + (1 − 𝑓𝑓𝑖𝑖)] (2c) 
The quantity Tout, also a function of droplet size, is the outward transmission rate 
(expelled by the infected person) for the barrier, and fi is the fraction of infected persons 
deploying RPDs.   
The initial conditions for the governing differential equations are: 
𝑆𝑆𝑟𝑟(0) = 𝑓𝑓𝑠𝑠  𝑆𝑆0   (3a) 
𝑆𝑆𝑛𝑛𝑟𝑟(0) = ( 1 − 𝑓𝑓𝑠𝑠  ) 𝑆𝑆0 (3b) 
𝐼𝐼(0) = 𝐼𝐼0   (3c) 
𝐷𝐷(0) = 0   (3d) 
𝑅𝑅(0) = 0   (3e), 
where S0 is the initial number of susceptibles, fs the initial fraction of susceptibles 
deploying RPDs, I0 the initial number of infecteds.     
6.3.2 Model Parameters 
In the simulations, parameter values specific to influenza outbreaks were used 
where possible.  Influenza specific parameter include the recovery rate µI (0.20 per day 





al., 2009)), the droplet removal rate 1/ν and the size distribution (described below).  
The breathing rate B was taken to be 24 m3d-1 for an adult and 7.2 m3d-1 for a five-year-
old child (Hinds, 2012).  The contact rate c was assumed to be the 13 times per day 
(Mossong et al., 2008) and the characteristic breathing time was equal to 35 min. The 
average deposition probability q for a droplet was determined by the ICRP's Lung 
Deposition Model (Guha et al., 2014; Hinds, 2012), assuming both the adults and 
children to be nose breathers, and an exposure time of 8 hours. The estimated 
deposition probabilities are shown in Appendix D (Table D1).   
Characteristics of a variety of RPDs were recently measured and published by 
Guha et al. (Guha et al., 2016).  In Guha et al. (2016), the inward transmission rate Tin 
and outward transmission rate Tout were written in terms of the protection factor PF 
commonly used to characterize barriers.  The relations are: 
𝑇𝑇𝑖𝑖𝑛𝑛 = 1/(𝑅𝑅𝑅𝑅𝑐𝑐𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑃𝑃𝑃𝑃) (4a) 
𝑇𝑇𝑜𝑜𝑜𝑜𝑑𝑑 = 1/(𝑆𝑆𝑆𝑆𝑆𝑆𝑅𝑅𝑐𝑐𝑅𝑅 𝑃𝑃𝑃𝑃)  (4b) 
The source and reciever PF’s for different droplet sizes are provided in Table 6.1.  
In our simulations, the following 6 RPDs were featured:  N95 respirators fitted for the 
user (adult), N95 respirators not fitted (adult user), low-filtration surgical mask (adult), 
adult high-filtration surgical mask (adult), high-filtration pediatric mask (child), and 
low-filtration pediatric mask (child).  The protection-factors for the masks and unfitted 
respirator are lower than that for the fitted respirator due to the presence of gaps 
between the device and the face (Brosseau, 2010; Brosseau and Harriman, 2007; Diaz 





not designed to protect against the spread of an epidemic, it was felt that in the event 
of a large-scale emergency, all the devices could potentially be used. 
6.3.3 Scenarios 
In the base case scenario, 20% of the susceptible and infected population wore the 
RPDs from the onset of the influenza season.  Both the susceptible and infected 
populations were in a closed community in which a single symptomatic case introduced 
influenza virus and initiated infection. The initial susceptible population was 1000. The 
droplet size distributions were bimodal, with bins centered at 0.5µm and 5µm.  
Other scenarios were constructed by changing the percentage of different RPDs 
deployed for both adult and child populations. Additional sensitivity analyses on values 
of key model parameters, such as the number of initial infected cases and the infectious 
contact rate were also explored. Additionally, to address the fact that in reality the 
distribution of airborne particles is polydisperse (Chao et al., 2009; Han et al., 2013; 
Holmgren et al., 2010; Nicas et al., 2005), different exposure particle size bins were 
also studied.  It is time consuming to incorporate all the size bins characterizing the 
particle distribution; hundreds of differential equations can result.  We considered 2, 3, 
and 4-size bins to evaluate the convergence rate of the solution as a function of the 
number of inhaled particle size bins. The characteristic sizes for the 2, 3, and 4 size 
bins were: (0.5 µm, 5 µm); (0.5 µm, 2.0 µm, 5 µm); (0.3 µm, 0.7 µm, 2.5 µm, 5 µm). 
The amount of respirable droplets within each size bin was determined based on 
Nicas.et al (Nicas et al., 2005).  The number of pathogens per droplet, transmission rate 
per inhaled droplet, respiratory-droplet production rate, gravitational settling rate, and 





Equations (1) – (3) were solved using a time-step 4th order Runge-Kutta method, 
as implemented in MATLAB (Version 8.6 (R2015b), Natick, Massachusetts: The 
MathWorks Inc., 2015).  The estimated epidemic curves, time to the peak day of the 
outbreak and the cumulative incidence rate (total percent of infection, CIR) are reported 
in the next section.  
  
Table 6.1. Protection factors for both source and receiver wearing different types of 
RPDs and exposed to different particle sizes 














Fitted N95 10 20 20 20 40 40 40 
Unfitted N95 7 2 2 2 2 2 2 
Low filtration 
surgical mask  3 1.1 1.1 1.1 1.1 1.1 1.1 
High filtration 
surgical mask 3 7 7 7 14 14 14 
Low filtration 
pediatric mask 3 2 2 2 2 2 2 
High filtration 











Figure 6.1. Influenza outbreak curves with varying RPDs and with 0%, 20%, 50% and 80% percentage of 






Figure 6.2. Influenza cumulative incidence rates with varying RPDs and with 0%, 20%, 50% and 80% 





6.4 Results  
 The prevalence of infection is plotted in Fig. 6.1 for the 6 different types of RPDs, 
assuming 4 levels of compliance in donning the RPDs:  0%, 20%, 50%, and 80%.  The 
level of compliance was assumed to be the same for the susceptible and infected 
populations.  The cumulative incidence is plotted in Fig. 6.2.   
In the case of adults with no protection (0% curves in Figs 6.1 and 6.2), the number 
of infected individuals at a given time reached a maximum of around 50% of the adult 
population and slightly over 40% of the pediatric population.  The maximum number 
of infections at a given time occurred at around day 10 for the adults and day 25 for the 
pediatric population (Fig. 6.1).  For both adults and children with no protection, 100% 
of the population was eventually infected (Fig. 6.2).  For the pediatric population, the 
infection spread at a slower rate, as evidenced by the broader distributions of the 
prevalence curves (Fig. 6.1) and the slower climb of the cumulative incidence curves 
(Fig. 6.2). 
At a 20% compliance rate, the decrease in the prevalence relative to no protection 
was about the same – roughly 30% - for the fitted N95 and the high-filtration surgical 
mask (Fig. 6.1).  The time for onset of the outbreak was not changed relative to the no-
protection scenario for either of these cases.  For the unfitted N95 and the low-filtration 
surgical mask, there was very little change in the onset time, infection prevalence, or 
cumulative incidence rate for 20% compliance compared with no use of RPDs.  For 
children, a decrease in prevalence of about 30% (low filtration pediatric mask) to 40% 





the 20% compliance rate.  The onset time increased by about 10 days for both pediatric 
masks.  The cumulative incidence rate decreased slightly – to about 80% for high-
filtration pediatric masks and 90% for low filtration pediatric masks (Fig. 6.2), 
compared to the no-protection scenario. 
At the 50% compliance rate, some significant protective effects can be observed.  
The prevalence dropped to about 10% for the high-filtration surgical mask and less than 
10% for the fitted respirator.  The unfitted N95 respirator exhibited approximately a 
25% infection prevalence, roughly half the value for case of no protection.  In terms of 
cumulative incidence, the fitted N95 results in enough protection that less than half (Fig 
6.2A) of the population becomes infected.  Approximately half of the population 
ultimately becomes infected with the high-filtration surgical mask (Fig. 6.2C).  For the 
unfitted N95 and the low-filtration surgical mask, nearly all of the population still 
ultimately becomes infected at the 50% compliance rate.  For children, both types of 
masks reduce the prevalence of infection significantly in the case of 50% compliance, 
by more than half relative to no protection for the low-filtration mask (Fig. 6.1F) and 
an order-of-magnitude for the high-filtration mask (Fig. 6.1E).  The time of maximum 
prevalence increases to around 60 days for the low-filtration pediatric mask and 90 
days for the high-filtration pediatric mask.  Regarding cumulative incidence for the 
50% compliance rate, by the end of 100 days approximately 30% of the pediatric 
population has been infected at some time for the high-filtration pediatric mask, and 
75% for the low-filtration pediatric mask. 
When 80% of the population deploys RPDs, an epidemic can be prevented with 





infection, was essentially zero for all adult and children’s forms of protection 
considered, except the low-filtration adult surgical mask (Figs. 6.1A, B, C, E, F, 2A, 
B, C, E, F).  For the low-protection adult surgical mask, the prevalence was reduced to 
about half of the no-protection value (Fig. 6.1D), and the cumulative incidence rate 
asymptotes at roughly 90%.   
The number of bins used in the analysis appeared to affect primarily the peak day 
(Table 6.2).  The cumulative incidence rate and duration of the outbreak were not 
significantly affected when 2, 3, or 4 bins were used.  
Table 6.2. Impact of different number of size bins, with 20% percentage of high filtration 
surgical masks wearing on influenza outbreaks 
 Types of aerosol distribution 
Two size bins 
(0.5 µm, 5 µm) 
Three size bins 
(0.5 µm, 2.0 
µm, 5.0 µm) 
Four size bins 
(0.3 µm, 0.7 µm, 2.5 
µm, 5 um) 
20% wearing fitted N95    
   Peak day 13 10 9 
   Cumulative incidence rate, % 81% 82% 83% 
   Outbreak duration 48 43 42 
20% wearing unfitted N95    
   Peak day 12 9 8 
   Cumulative incidence rate, % 98% 99% 99% 
   Outbreak duration 47 44 42 
20% wearing high filtration 
surgical mask 
   
   Peak day 12 10 8 
   Cumulative incidence rate, % 85% 87% 89% 
   Outbreak duration 48 45 44 
20% wearing low filtration 
surgical masks 
   
   Peak day 10 8 7 
   Cumulative incidence rate, % 99% 99% 99% 






The fraction of the population ultimately infected was not sensitive to the number 
of individuals initially infected (Table 6.3).  The outbreak of the infection decreased 
from 48 days to 43 days, and the day of maximum prevalence decreased from day 12 
to day 7, as the number of initial infecteds increased from 1 to 30.  
An increase in the average of number contacts between a susceptible and infecteds 
from 13 to 20 per day increased the cumulative incidence rate from 85% to 88% of the 
population (Table 6.3).  This increase was accompanied by a decrease in outbreak 
duration from 48 days to 43.  A decrease in the average number of contacts from 13 to 
10 per day reduced the cumulative incidence rate from 85% to 82%, and increased the 
outbreak duration from 48 days to 54. 
 
Table 6.3. Sensitivity analyses exploring the impact of changing selected parameter 








No. initial infected case    
 1 symptomatic case (base case) 12 85% 48 
 10 symptomatic cases 9 85% 45 
 20 symptomatic cases 8 85% 44 
 30 symptomatic cases 7 85% 43 
Contact rate between a 
susceptible and an infected    
 13 contacts/day (base case) 12 85% 48 
 +25% from base case 9 87% 44 
 +50% from base case 8 88% 43 






6.5 Discussion  
Simulations revealed that a 20% compliance rate for people wearing RPDs showed 
some utility in reducing the spread of infection if the highest protection-factor devices 
(e.g. PF > 7) were deployed, but overall did have a big impact on the spread of infection 
due to the influenza virus.  At a 50% compliance rate, however, the effect of the 
influenza outbreak was significantly reduced (prevalence cut by at least half) by all 
barriers except the low-filtration adult surgical mask.  At 80% compliance, an influenza 
outbreak is essentially prevented by all of the RPDs except the low-filtration surgical 
mask.   We conclude on the basis of the simulations that a roughly 50% compliance 
rate is recommended in order for RPDs that are likely to be used on an emergency basis 
for to constitute an effective countermeasure.  We also conclude that low-filtration 
surgical masks (PF ≤ 2) for adults would not provide an effective countermeasure even 
as a high rate of compliance, consistent with the fact that the masks were not designed 
for that purpose. 
The compliance rate for both the susceptible and infected populations was taken 
to be the same (20%).  That doesn’t necessarily imply that attention to the source and 
receiver played equally important roles, because the protection factor for a given barrier 
can be different in the incoming and outgoing directions.  A fitted N95 respirator, for 
example, is roughly 4 times more effective in limiting the influx of influenza virus of 
size 2µm than it is in limiting the outgoing flux of that pathogen.  The difference 
between source and receiver protection factors can be taken into account in devising a 
protection strategy. A higher protection factor can compensate for a lower degree of 





infected cases and contract rate could result in an early outbreak and early peak day, 
since susceptibles will have a higher chance to inhale infectious droplets and initiate 
infection earlier. 
The rate of infection for the pediatric population was lower than that for the adult 
population, owing to the lower breathing rate.  The differences in immune response 
between adults and children was not accounted for in the model.  A weaker immune 
system in children could be accounted for in a lower value of the infection recovery 
rate µI.  
The results of the present model are potentially useful in designing a 
countermeasure strategy against an influenza outbreak.  Providing all adults fitted N95 
respirators clearly provides the highest level of protection.  However, the availability 
of N95 respirators may be limited by financial constraints, or there may not be 
sufficient time to perform fitting.  The high pressure differential across N95 respirators 
(Guha et al., 2016) may make them an infeasible choice for extended wear by 
individuals with difficulty breathing.  The present model can be used to compute the 
increase in risk associated with other choices of protection. Another important 
application of the model is the determination of the level of compliance required for a 
certain level of reduction in the risk of infection by influenza.  Knowing the level of 
compliance required, public-health officials can devise education strategies.  Finally, 
the model described in this chapter can be used to evaluate new types of protective 
equipment, or existing equipment against new pathogens, in a manner that provides 
actual estimates of infection rate rather than just a measure of the transmission rate 





Ideally, the results of the model should be validated against experimental data.  
Acquiring validation data is very difficult, due the inability to deliberately infect a 
control population.  In the future, it is hoped that the model can be partially validated 
in a classroom or dormitory situation, with naturally infected individuals willing to 
commit to a regimen involving RPDs.  For the present, we note that while the accuracy 
of the absolute predictions of infection rate is unclear, we expect that relative 
predictions of infection prevalence, e.g. between different levels of compliance, is 
likely to be more reliable. 
6.6 Conclusion 
 
A risk-assessment model previously developed in general form was used to 
estimate the effectiveness of different types of protective equipment in reducing the 
rate of infection in an influenza outbreak.  It was found that a 50% compliance in 
donning the device resulted in a significant (at least 50% prevalence and 20% 
cumulative incidence) reduction in risk for fitted and unfitted N95 respirators, high-
filtration surgical masks, and both low-filtration and high-filtration pediatric masks.   
An 80% compliance rate essentially eliminated the influenza outbreak.  The results of 
the present study, as well as the application of the model to related influenza scenarios, 
are potentially useful to public-health officials in decisions involving resource 






CHAPTER 7: CONCLUSIONS AND FUTURE WORK 
7.1 Conclusions 
The G-II has been characterized for the ability to maintain virus infectivity and to 
efficiently collect submicron particles while operating at high flow rate. In the UMD 
EMIT study, the presence of culturable influenza virus in nearly 40% of the fine aerosol 
samples demonstrates that influenza cases shed infectious virus as well as RNA into 
airborne droplets and contributes to the biological plausibility and likely importance of 
airborne influenza transmission. However, cough was not a strong predictor of 
infectious aerosol generation suggesting an important role for other mechanisms of 
aerosol generation. The nasal shedding and aerosol shedding are independent, and only 
the viral load in NP swab but not the aerosol sample is associated with upper respiratory 
symptoms. The results suggest that aerosol particle samples are generated from the 
deep lung and are not correlated with the viral content in the upper respiratory tract.  
From the three climates study, environmental effects showed no influence on shedding 
of virus into exhaled breath, but fine aerosol fraction has significantly higher viral 
content than in the coarse fraction samples across different climates, which has 
suggested an important role for airborne transmission in temperate, subtropical and 
tropical areas.   
To understand the spread of airborne disease and how the RPDs play an effect on 
epidemics, the mathematical model discussed in this dissertation deployed protective 
measures by dividing the susceptible population into two groups, one of which deploys 





RPDs, thereby reducing the source of pathogens. The model also has the ability to track 
the initial dynamics of the infected population. This ability could prove useful, for 
example, in identifying the time interval available for medical assistance to arrive 
before the infected population reaches a certain size, as a function of the properties of 








7.2 Future Work  
7.2.1 Development of A New Device  
The G-II collects samples in around 135 ml liquid during 30 minutes of sampling. 
The goal of designing an improved device, the G-III, is to collect the exhaled droplets 
with liquid volumes much smaller than the existing G-II device.  It will alleviate the 
losses during cell-culture and improve the testing sensitivity. The current G-III design 
is the combination of a 100 L/min wetted wall cyclone and the G-II with standpipes 
built in (Figure 7.1). The wetted wall cyclone as the first stage will collects droplets 
larger than 5 µm in diameter. The cyclone collected droplets into around 3mL of 
aqueous fluid for 15 min and make the liquid immediately available for analysis. The 
peristaltic pump that is connected to the condenser drain could constantly pull out the 
condensing liquid on G-II over the sampling time and reduce the amount of collected 
liquid down to 25 ml over 15 min of collection. The collection efficiency (with 
reference to SKC BioSampler) of the combined collectors was evaluated with three 
sizes of fluorescent PSL particles, 1 µm, 3.1 µm, and 9.9 µm, respectively. Three 
samples were collected for each size, and the sampling time for each sample was 15 
minutes. I recovered 85% of 1 µm from the collectors, for d = 3.1 µm PSL spheres, I 
recovered 128% from the collectors, and 115% recovery from the collectors with 9.9 
µm PSL particles. The experimental results showed that the design can be used to 





Future work can be done by designing a more portable device, which combines the 
features of both wetted wall cyclone and G-II and collects the particles in an even 
smaller volume of liquid. Two flow rate devices can be developed to meet different 
study purposes. The low flow rate (30 L/min) device can be used for biomarker 
discovery and testing for specific antibodies in exhaled breath air. The low flow rate 
design will require a mouthpiece supplied with filtered air and nose clip to specifically 
collect and isolate the exhaled breath air from background aerosols. The subjects will 
be asked to use special breathing maneuvers to increase airway closure and particle 
generation.  Another high flow (130 L/min) version can incorporate a HEPA filtered 
air supplied booth in which a subject will sit facing the inlet of the collector and breath 
normally and shed respiratory particles and his/her personal aerosol into the booth. This 
high flow version will be used with microfluidic lab on a chip system and perform real-
time bio-surveillance of individuals. The new designs could also be used at sites of 
emerging infection outbreaks to prevent the commuting issue for volunteers who 
participate in the flu study during their illness to give samples of their exhaled breath. 





Experiments need to be conducted to test if the new designs could efficiently maintain 
the viability of different virus strains.  
7.2.2 Modeling of Influenza Epidemics 
Our study, by analyzing the modified SIR model, could give a theoretical 
framework for public health interventions. The results support the idea that RPD 
protection significantly reduces the spread of influenza via airborne transmission. The 
model could play an important role in planning initial intervention strategies and 
predicting the growth rate of an epidemic. However, the study findings were based on 
a deterministic model and need to be interpreted with caution. The parameter estimates 
were taken from the published literature and the sensitive analysis showed how the 
results were affected by changing the key parameter values. The model did not take 
into consideration pharmaceutical interventions and the air quality control in a closed 
environment. Vaccinating susceptible individuals could remove them from the 
susceptible group in the SIR model (Guha et al., 2016), and improving air quality could 
reduce the transmission rate by weakening the source strength (Tuomi, 1985). Future 
mathematical models can be performed to implement these factors in the influenza 
transmission mechanism. Clinical studies with human volunteers could be conducted 
within a university or elementary schools by recruiting naturally infected influenza 
cases and have them wearing protective devices to validate the results generated in this 
model. The process of conducting such experiments is challenging. It is hard to monitor 





In future work, use of models with further immunological details of infectious 
mechanisms will be a key approach (Nicas et al., 2005). It will help rationalize the 
criteria for effective control of disease transmission with a better understanding of the 
pathogenesis mechanism (Zambon, 1999). Empirical data linking the interactions of 
disease transmission and control is needed for further model validation. To be better 
prepared for an imminent influenza pandemic or the emergence of new viral infection, 
it is extremely important to understand the dynamics of diseases in population and 
communities. Reproducing epidemiological observations from public health data by 
translating biological, medical and social processes into mathematical models will be 

































Table A1. Average G-II operating parameters during sample collection 
 Subject 1 Subject 2 Subject 3 
Booth air temperature [oC] 26.6 26.7 27 
Booth air humidity [%] 80 80 77 
Mass flow rate of steam [kg/s] 0.000031 0.000031 0.000033 
Air temperature after the condenser [oC] 7.2 7.2 7.4 
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Figure B4. Viral shedding in swabs and aerosol samples and the effect of sneeze: A) RNA 
copies in NP swabs, coarse, and fine aerosols; B) infectious influenza virus in NP swabs and 
fine aerosols; C) RNA copies stratified by observed number of sneezes in coarse aerosols, and 
D) in fine aerosols. NP = nasopharyngeal swab, Coarse Aerosol = droplets > 5 µm and Fine 







                    A                                                               B 
                     
       C                                               D                                                    E       
        
                       F                                                                            G 
                       
Figure B5. Scatter plots and Spearman correlation coefficients of focus counts versus RNA copies for NP (A) and fine (B) 
samples.  Scatter plots and Spearman correlation coefficients of RNA copies versus cough/min for NP (C), coarse (D) and 






NP swabs were eluted in 1 mL of elution medium consisting of either phosphate 
buffered saline supplemented with 0.1% bovine serum albumin (PBS/0.1% BSA) or 
universal transport medium [UTM, Copan, Murrieta, CA].  Teflon® impactors were 
scrubbed using nylon Floq'd swab [Copan, Murrieta, CA] saturated with PBS/0.1% 
BSA. The end of the swab was cut off and placed in a tube containing 1 ml PBS/0.1% 
BSA. The tube was vortexed for 1 minute at full speed, to elute material from the 
swab, and the swab head was removed. Fine aerosol buffer samples were 
concentrated to 1 mL using a CentriconPlus-70 centrifugal ultrafiltration device with 
a nominal molecular weight cut-off of 100 KDa. All processed samples were stored 
either at 4 degrees until they could be analyzed for infectious virus or they were 
stored at –80 C until they could be analyzed for viral RNA.   
RNA was extracted from each sample type using a QIAamp Minelute virus spin 
kit (Qiagen, Hilden, Germany) executed on a Qiacube liquid handling device. 
Taqman chemistry was used for the RT-qPCR assays, and Primer/probe sets designed 
at the US Center for Disease Control and Prevention for the detection of influenza B 
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and for the detection and subtyping of influenza A. Whole virion standards that had 
been quantitated by electron microscopy were used to generate standard curves, and 
those standard curves were calibrated against plasmid DNA containing the targets of 
either the influenza A or influenza B RT-qPCR reaction.   
Virus culture of the NP swabs and fine aerosol fractions on Madin-Darby Canine 
kidney (MDCK) cells was used to identify samples with infectious virus. Culture was 
performed within 12 hours of sample collection, and cell monolayers were observed 
on the 4th day post-inoculation. Samples that did not exhibit cytopathic effect on the 
4th day post-inoculation were transferred to fresh cell monolayers and incubated for 
an additional 4 days. Monolayers that exhibited cytopathic effect on either the 4th or 
the 8th day post-inoculation were considered infectious virus-positive. Samples with 
bacterial or fungal contaminants or not processed within 12 hours were rejected. 
Samples from the course aerosol fraction were not cultured, as they were not expected 
to contain infectious virus given the collection conditions of that aerosol fraction.  
Infectious virus in the NP swab and the concentrated fine-particle aerosol was 
quantified using an immunofluorescence assay. MDCK cells were incubated with the 
samples at room temperature for 1 h, and then the temperature was shifted to 37 C to 
allow for virus entry to occur. After an hour at 37 C, medium containing fetal bovine 
serum was added to the culture and the cells were incubated for an additional 8 hours. 
The addition of the serum serves two purposes. First it helps to maintain integrity and 
morphology of the cells, and it limits infection to a single round of replication by 
inactivating extracellular trypsin in the culture that is required for the cleavage of 





not infectious. Cells were fixed with ice-cold 80% acetone, and were stained for 
influenza A and B nucleoprotein using primary antibodies AA5h and sc-57885 
[Abcam, Cambridge UK, and Santa Cruz Biotechnoloy, Santa Cruz, CA, 
respectively] followed by a goat anti-mouse secondary antibody conjugated with 
Alexa-Fluor488 [ThermoFisher Scientific, Waltham MA]. Positive cells were counted 










Tobit Model SAS code 
 
 





data  pcrtotal; 
set  pcrtotal ; 
if fine_final_copies ~=. then logfine=log10(fine_final_copies); 
if fine_final_copies  =. and typeAB='A' then logfine=log10(2000); 
if fine_final_copies  =. and typeAB='B' then logfine=log10(9000); 
run;quit; 
data pcrtotal; 
set pcrtotal ; 
  if np_final_copies ~=. then lognp=log10(np_final_copies); 
if np_final_copies  =. and typeAB='A' then lognp=log10(8000); 




if coarse_final_copies ~=. then 
logcoarse=log10(coarse_final_copies); 
if coarse_final_copies  =. and typeAB='A' then 
logcoarse=log10(2000); 




/* Effect of np swab PCR results on the fine and coarse samples, 
Does the NP results reflect the amount of RNA copies in the exhaled 
breath samples ? */ 
proc genmod data = pcrtotal; 
  class  subject_id finesampleid ; 
  model logfine= lognp/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
run; 
proc nlmixed data=pcrtotal XTOL=1E-12 method=GAUSS qpoints=100; 





 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&unfBeta0 
beta1=&unfBeta1 ; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*lognp; 
 if fine_final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) 
* exp( -(logfine-mu)**2 / (2*sigma2) ); 
 if fine_final_copies = .  then ll = probnorm( (logfine - mu) / 
sqrt(sigma2) ); 
 L=log(ll); 
 model logfine~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




  proc genmod data = pcrtotal; 
  class  subject_id coarsesampleid; 
  model logcoarse= lognp/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('uncBeta0', COL1 ); 
 call symput('uncBeta1', COL2 ); 
run; 
proc nlmixed data=pcrtotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of coarse Particles: Effect of logNP"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&uncBeta0 
beta1=&uncBeta1; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j + b_1j+ beta1*lognp; 
 if coarse_final_copies ne . then ll = (1 / 
(sqrt(2*pi*sigma2))) * exp( -(logcoarse-mu)**2 / (2*sigma2) ); 
 if coarse_final_copies = .  then ll = probnorm( (logcoarse - 
mu) / sqrt(sigma2) ); 
 L=log(ll); 
 model logcoarse~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 














data  pcrtotal; 
set  pcrtotal ; 
if final_copies ~=. and Fine=1  then 
logfinalcopies=log10(final_copies); 
if final_copies  =. and Fine=1 and typeAB='A' then 
logfinalcopies=log10(2000); 




set pcrtotal ; 
  if final_copies ~=. and NPswab=1 then 
logfinalcopies=log10(final_copies); 
if final_copies  =. and NPswab=1 and typeAB='A' then 
logfinalcopies=log10(8000); 
if final_copies  =. and NPswab=1 and typeAB='B' then 
logfinalcopies=log10(36000); 
 run;quit; 
 data pcrtotal; 
set pcrtotal; 
if final_copies ~=. and Coarse=1 then 
logfinalcopies=log10(final_copies); 
if final_copies  =. and Coarse=1 and typeAB='A' then 
logfinalcopies=log10(2000); 














if NPswab= 0 then delete; 
run;quit; 
proc nlmixed data= finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 1 beta0=4 ; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi');  
 mu = beta0 + b_0j +b_1j; 
 if  final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if  final_copies = .  then ll = probnorm( (logfinalcopies - 
mu) / sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 








proc nlmixed data= coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 1 beta0=4 ; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi');  
 mu = beta0 + b_0j +b_1j; 
 if  final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if  final_copies = .  then ll = probnorm( (logfinalcopies - 
mu) / sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




proc nlmixed data= nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 1 beta0=4 ; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi');  
 mu = beta0 + b_0j +b_1j; 
 if  final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if  final_copies = .  then ll = probnorm( (logfinalcopies - 
mu) / sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




/*Age as continuous*/ 
 
 proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= age/ dist=poisson ; 
  repeated subject = subject_id/printmle; 




set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('cfBeta1', COL2 ); 
 call symput('cfBeta0', COL1 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles: Effect of age"; 






 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*age; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




   proc genmod data = coarsetotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= age/dist=poisson; 
  repeated subject =  subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ccBeta1', COL2 ); 
 call symput('ccBeta0', COL1 ); 
run; 
 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of age"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ccBeta0 
beta1=&ccBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j+ + beta1*age; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





  proc genmod data = nptotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= age/dist=poisson; 
  repeated subject =  subject_id/ printmle; 







set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ccBeta1', COL2 ); 
 call symput('ccBeta0', COL1 ); 
run; 
 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP swab Particles: Effect of Age"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ccBeta0 
beta1=&ccBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j+ + beta1*age; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




/*cough as continuous*/ 
 proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= cough_number/ dist=poisson ; 
  repeated subject = subject_id/printmle; 




set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('cfBeta1', COL2 ); 
 call symput('cfBeta0', COL1 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles: Effect of Cough"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&cfBeta0 
beta1=&cfBeta1; 





 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*cough_number; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




   proc genmod data = coarsetotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= cough_number/dist=poisson; 
  repeated subject =  subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ccBeta1', COL2 ); 
 call symput('ccBeta0', COL1 ); 
run; 
 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of Cough"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ccBeta0 
beta1=&ccBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j+ + beta1* cough_number; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





  proc genmod data = nptotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= cough_number/dist=poisson; 
  repeated subject =  subject_id/ printmle; 







set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ccBeta1', COL2 ); 
 call symput('ccBeta0', COL1 ); 
run; 
 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP swab Particles: Effect of Cough"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ccBeta0 
beta1=&ccBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j+ + beta1* cough_number; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




/*cough as categorical */ 
data finetotal; 
set finetotal; 
if 0< cough_number <30 then X1 = 1; else X1 = 0; 
if cough_number GE 30 then X2 = 1; else X2 = 0; 
 run;quit; 
proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= X1 X2/ dist=poisson ; 
  repeated subject = subject_id/printmle; 




set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('cfBeta1', COL2 ); 
 call symput('cfBeta0', COL1 ); 






proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles: Effect of Cough"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&cfBeta0 
beta1=&cfBeta1 beta2=&cfBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1 +  beta2*X2 ; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 






if 0< cough_number <30 then X1 = 1; else X1 = 0; 
if cough_number GE 30 then X2 = 1; else X2 = 0; 
 run;quit; 
   proc genmod data =coarsetotal; 
  class  subject_id sampleid; 
  model logfinalcopies=  X1 X2/dist=poisson; 
  repeated subject =  subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('cfBeta1', COL2 ); 
 call symput('cfBeta0', COL1 ); 
  call symput('cfBeta2', COL3 ); 
run; 
 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of Cough"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&cfBeta0 
beta1=&cfBeta1 beta2=&cfBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j+ + beta1*X1 +  beta2*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 











if 0< cough_number <30 then X1 = 1; else X1 = 0; 
if cough_number GE 30 then X2 = 1; else X2 = 0; 
 run;quit; 
   proc genmod data =nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies=  X1 X2/dist=poisson; 
  repeated subject =  subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('cfBeta1', COL2 ); 
 call symput('cfBeta0', COL1 ); 
  call symput('cfBeta2', COL3 ); 
run; 
 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of Cough"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&cfBeta0 
beta1=&cfBeta1 beta2=&cfBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j+ + beta1*X1 +  beta2*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




/* Day post onset,for fine and coarse samples */ 
data finetotal; 
set finetotal; 
 if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
  
 proc genmod data = finetotal ; 
  class  subject_id sampleid; 





   repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fdpoBeta0', COL1 ); 
 call symput('fdpoBeta1', COL2 ); 
 call symput('fdpoBeta2', COL3 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles: Effect of 
day_post_onset"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fdpoBeta0 
beta1=&fdpoBeta1 beta2=&fdpoBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1+ beta2*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 






 if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
  proc genmod data = coarsetotal; 
  class  subject_id sampleid; 
  model  logfinalcopies= X1 X2/dist=poisson; 
   repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('cdpoBeta0', COL1 ); 





 call symput('cdpoBeta2', COL3 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of day post 
onset"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&cdpoBeta0 
beta1=&cdpoBeta1 beta2=&cdpoBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1+ beta2*X2 ; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model  logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 







 if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
  
 proc genmod data = nptotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= X1 X2/dist=poisson; 
   repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fdpoBeta0', COL1 ); 
 call symput('fdpoBeta1', COL2 ); 
 call symput('fdpoBeta2', COL3 ); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles: Effect of 
day_post_onset"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fdpoBeta0 
beta1=&fdpoBeta1 beta2=&fdpoBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1+ beta2*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 





 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




/* Effect of Asthma for NP, Fine and coarse */ 
 proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= asthma/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('faBeta1', COL2 ); 
 call symput('faBeta0', COL1 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles: Effect of Asthma"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&faBeta0 
beta1=&faBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*asthma; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




 proc genmod data = coarsetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= asthma/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 








 set Paramst; 
 call symput('caBeta1', COL2 ); 
 call symput('caBeta0', COL1 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of Asthma"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&caBeta0 
beta1=&caBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*asthma; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





 proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies= asthma/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('naBeta1', COL2 ); 
 call symput('naBeta0', COL1 ); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: Effect of Asthma"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&naBeta0 
beta1=&naBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*asthma; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 





 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




/* Effect of subtype for NP,Fine and coarse */ 
data finetotal; 
set finetotal; 
 If typeAB='A' then fineA=1;else fineA=0; 
 run;quit; 
 proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= fineA/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fsBeta1', COL2 ); 
 call symput('fsBeta0', COL1 ); 
run; 
 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles: Effect of subtypes"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fsBeta0 
beta1=&fsBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*fineA; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 






 If typeAB='A' then coarseA=1;else coarseA=0; 
 run;quit; 
 proc genmod data = coarsetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= coarseA/dist=poisson; 
 repeated subject = subject_id/ printmle; 







set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('csBeta1', COL2 ); 
 call symput('csBeta0', COL1 ); 
run; 
 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of subtype"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&csBeta0 
beta1=&csBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*coarseA;; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 






 If typeAB='A' then npA=1;else npA=0; 
 run;quit; 
 proc genmod data =nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies= npA/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('nsBeta1', COL2 ); 
 call symput('nsBeta0', COL1 ); 
run; 
 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 





 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&nsBeta0 
beta1=&nsBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*npA; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




/* Effect of feverishness for NP, Fine and coarse */ 
data finetotal; 
set finetotal; 
 If body_temp GE 37.8 then fever = 1; else fever = 0; 
 run;quit; 
 proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= fever/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ftBeta1', COL2 ); 
 call symput('ftBeta0', COL1 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles: Effect of fever"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ftBeta0 
beta1=&ftBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*fever; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 










 If body_temp GE 37.8 then fever = 1; else fever = 0; 
 run;quit; 
 proc genmod data = coarsetotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= fever/dist=poisson; 
  repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ctBeta1', COL2 ); 
 call symput('ctBeta0', COL1 ); 
run; 
 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of fever"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ctBeta0 
beta1=&ctBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*fever; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 






 If body_temp GE 37.8 then fever = 1; else fever = 0; 
 run;quit; 
 proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies= fever/dist=poisson; 
repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 








 set Paramst; 
 call symput('ntBeta1', COL2 ); 
 call symput('ntBeta0', COL1 ); 
run; 
 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: Effect of fever"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ntBeta0 
beta1=&ntBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*fever; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 










 If 37<body_temp <38 then X1 = 1; else X1 = 0; 
 if body_temp GE 38   then X2=1; else X2=0; 
 run;quit; 
proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies=X1 X2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ftBeta1', COL2 ); 
 call symput('ftBeta0', COL1 ); 
  call symput('ftBeta2', COL3); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 






 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ftBeta0 
beta1=&ftBeta1 beta2=&ftBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1 + beta2*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 






 If 37<body_temp <38 then X1 = 1; else X1 = 0; 
 if body_temp GE 38   then X2=1; else X2=0; 
 run;quit; 
proc genmod data = coarsetotal; 
  class  subject_id sampleid; 
  model logfinalcopies=X1 X2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ftBeta1', COL2 ); 
 call symput('ftBeta0', COL1 ); 
  call symput('ftBeta2', COL3); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of body_temp as 
three catogories"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ftBeta0 
beta1=&ftBeta1 beta2=&ftBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1 + beta2*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 











 If 37<body_temp <38 then X1 = 1; else X1 = 0; 
 if body_temp GE 38   then X2=1; else X2=0; 
 run;quit; 
proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies=X1 X2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ftBeta1', COL2 ); 
 call symput('ftBeta0', COL1 ); 
  call symput('ftBeta2', COL3); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: Effect of body_temp as 
three catogories"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ftBeta0 
beta1=&ftBeta1 beta2=&ftBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1 + beta2*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





/* Effect of vaccination for NP,Fine and coarse */ 
 proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= fluvac_cur/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 











 set Paramst; 
 call symput('fvBeta1', COL2 ); 
 call symput('fvBeta0', COL1 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles: Effect of Vaccination"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fvBeta0 
beta1=&fvBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*fluvac_cur; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




 proc genmod data = coarsetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= fluvac_cur/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('cvBeta1', COL2 ); 
 call symput('cvBeta0', COL1 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of Vaccination"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&cvBeta0 
beta1=&cvBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*fluvac_cur; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 






 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




 proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies= fluvac_cur/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('nvBeta1', COL2 ); 
 call symput('nvBeta0', COL1 ); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: Effect of Vaccination"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&nvBeta0 
beta1=&nvBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*fluvac_cur; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model  logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





/*Study the three categories for three groups of symptom score with 
the PCR results (NP, Fine, Coarse) 
Set one category in each group as the reference( ß0) 
Upper: x<=7, 7<x<10, x>=10  
Lower: y<=3,3<y<5, x>=5 




 If 7<upper_sym<10 then X1 = 1; else X1 = 0; 
If upper_sym GE 10 then X2 = 1; else X2 = 0; 
If 3<lower_sym<5 then Y1 = 1; else Y1 = 0; 
If lower_sym GE 5 then Y2 = 1; else Y2 = 0; 





If systemic_sym GE 7 then Z2 = 1; else Z2 = 0; 
 run;quit; 
proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= X1 X2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 
 call symput('fuperBeta1', COL2 ); 
 call symput('fuperBeta2', COL3 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of three 
catogories of upper respiratory symptoms"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1 beta2=&fuperBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1 + beta2*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= Y1 Y2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('flowerBeta0', COL1 ); 





 call symput('flowerBeta2', COL3 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of three 
catogories of lower respiratory symptoms"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&flowerBeta0 
beta1=&flowerBeta1 beta2=&flowerBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*Y1 + beta2*Y2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= Z1 Z2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fsystemicBeta0', COL1 ); 
 call symput('fsystemicBeta1', COL2 ); 
 call symput('fsystemicBeta2', COL3 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of three 
catogories of Systemic symptoms"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 
beta0=&fsystemicBeta0 beta1=&fsystemicBeta1 beta2=&fsystemicBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*Z1 + beta2*Z2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 












 If 7<upper_sym<10 then X1 = 1; else X1 = 0; 
If upper_sym GE 10 then X2 = 1; else X2 = 0; 
If 3<lower_sym<5 then Y1 = 1; else Y1 = 0; 
If lower_sym GE 5 then Y2 = 1; else Y2 = 0; 
If 4<systemic_sym<7 then Z1 = 1; else Z1 = 0; 
If systemic_sym GE 7 then Z2 = 1; else Z2 = 0; 
 run;quit; 
proc genmod data = coarsetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= X1 X2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('cuperBeta0', COL1 ); 
 call symput('cuperBeta1', COL2 ); 
 call symput('cuperBeta2', COL3 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of coarse Particles: Effect of three 
catogories of upper respiratory symptoms"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&cuperBeta0 
beta1=&cuperBeta1 beta2=&cuperBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1 + beta2*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




proc genmod data = coarsetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= Y1 Y2/dist=poisson; 
 repeated subject = subject_id/ printmle; 







set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('clowerBeta0', COL1 ); 
 call symput('clowerBeta1', COL2 ); 
 call symput('clowerBeta2', COL3 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of coarse Particles: Effect of three 
catogories of lower respiratory symptoms"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&clowerBeta0 
beta1=&clowerBeta1 beta2=&clowerBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*Y1 + beta2*Y2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




proc genmod data = coarsetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= Z1 Z2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('csystemicBeta0', COL1 ); 
 call symput('csystemicBeta1', COL2 ); 
 call symput('csystemicBeta2', COL3 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of three 
catogories of Systemic symptoms"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 
beta0=&csystemicBeta0 beta1=&csystemicBeta1 beta2=&csystemicBeta2; 





 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*Z1 + beta2*Z2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 






 If 7<upper_sym<10 then X1 = 1; else X1 = 0; 
If upper_sym GE 10 then X2 = 1; else X2 = 0; 
If 3<lower_sym<5 then Y1 = 1; else Y1 = 0; 
If lower_sym GE 5 then Y2 = 1; else Y2 = 0; 
If 4<systemic_sym<7 then Z1 = 1; else Z1 = 0; 
If systemic_sym GE 7 then Z2 = 1; else Z2 = 0; 
 run;quit; 
proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies= X1 X2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('nuperBeta0', COL1 ); 
 call symput('nuperBeta1', COL2 ); 
 call symput('nuperBeta2', COL3 ); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: Effect of three catogories 
of upper respiratory symptoms"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&nuperBeta0 
beta1=&nuperBeta1 beta2=&nuperBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1 + beta2*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 









proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies= Y1 Y2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('nlowerBeta0', COL1 ); 
 call symput('nlowerBeta1', COL2 ); 
 call symput('nlowerBeta2', COL3 ); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: Effect of three catogories 
of lower respiratory symptoms"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&nlowerBeta0 
beta1=&nlowerBeta1 beta2=&nlowerBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*Y1 + beta2*Y2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies= Z1 Z2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 









 call symput('nsystemicBeta0', COL1 ); 
 call symput('nsystemicBeta1', COL2 ); 
 call symput('nsystemicBeta2', COL3 ); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: Effect of three catogories 
of Systemic symptoms"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 
beta0=&nsystemicBeta0 beta1=&nsystemicBeta1 beta2=&nsystemicBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*Z1 + beta2*Z2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 









  if chiller_t GE 30 then X1=1 ; else X1 = 0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= X1 /dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of chillertemp"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 





 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 









   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies=cough_number X1 X2 systemic_sym/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of  cough_num dpo2 
dpo3, systemic"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*systemic_sym; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 














   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
  proc genmod data = coarsetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies=cough_number X1 X2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of  cough_num 
dpo2 dpo3"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 ; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




/* effect of chiller temperature and condenser in and out 







  if chiller_t GE 32 then X1=1 ; else X1 = 0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= X1 cond_tin cond_tout/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
run; 
proc nlmixed data= finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of chillertemp 
cond_Tin cond_Tout"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*X1 + beta2*cond_tin + 
beta3*cond_tout; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




/*Effect of chiller temperature, elbow relative humidity and elbow 
temperature on fine fraction samples*/ 
data finetotal; 
set  finetotal; 
  if chiller_t GE 32 then X1=1 ; else X1 = 0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= X1 elbow_rh elbow_t/dist=poisson; 
 repeated subject = subject_id/ printmle; 







set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of chillertemp 
elbow_rh elbow_t"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*X1 + beta2*elbow_rh + 
beta3*elbow_t; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 










proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= upper_sym/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 






proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of upper symptoms 
as continuous"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*upper_sym; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= lower_sym/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 
 call symput('fuperBeta1', COL2 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of lower symptoms 
as continuous"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*lower_sym; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 









  class  subject_id sampleid; 
  model logfinalcopies= systemic_sym/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 
 call symput('fuperBeta1', COL2 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of Systemic 
symptoms as continuous"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*systemic_sym; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





proc genmod data = coarsetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= upper_sym/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 
 call symput('fuperBeta1', COL2 ); 
run; 





Title "Tobit Regression of Coarse Particles: Effect of upper 
symptoms as continuous"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*upper_sym; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




proc genmod data = coarsetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= lower_sym/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 
 call symput('fuperBeta1', COL2 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of lower 
symptoms as continuous"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*lower_sym; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




proc genmod data = coarsetotal; 





  model logfinalcopies= systemic_sym/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 
 call symput('fuperBeta1', COL2 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of Systemic 
symptoms as continuous"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*systemic_sym; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies= upper_sym/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 
 call symput('fuperBeta1', COL2 ); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 






 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*upper_sym; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies= lower_sym/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 
 call symput('fuperBeta1', COL2 ); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: Effect of lower symptoms as 
continuous"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*lower_sym; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies= systemic_sym/dist=poisson; 





  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 
 call symput('fuperBeta1', COL2 ); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: Effect of Systemic symptoms 
as continuous"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*systemic_sym; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 







if NPswab= 1 then delete; 
run;quit; 
proc genmod data = finecoarse; 
  class  subject_id sampleid; 
  model logfinalcopies= Coarse/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 
 call symput('fuperBeta1', COL2 ); 
run; 





Title "Tobit Regression of Fine and Coarse logviruscopies 
comparison"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*Coarse; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





set  finecoarse; 
  if Coarse=1 then X1=1 ; else X1 = 0; 
 run;quit; 
proc genmod data = finecoarse; 
  class  subject_id sampleid; 
  model logfinalcopies= X1/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 
 call symput('fuperBeta1', COL2 ); 
run; 
proc nlmixed data=finecoarse XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine and Coarse logviruscopies 
comparison"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 









/*Within flu A, compare virus copy number of fine and coarse*/ 
data finecoarseA; 
set pcrtotal; 
if NPswab= 1 | typeAB='B'  then delete; 
run;quit; 
proc genmod data = finecoarseA; 
  class  subject_id sampleid; 
  model logfinalcopies= Coarse/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 
 call symput('fuperBeta1', COL2 ); 
run; 
proc nlmixed data=finecoarseA XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine and Coarse logviruscopies 
comparison"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*Coarse; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 









if NPswab= 1 | typeAB='A'  then delete; 
run;quit; 
proc genmod data = finecoarseB; 
  class  subject_id sampleid; 
  model logfinalcopies= Coarse/dist=poisson; 
 repeated subject = subject_id/ printmle; 







set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fuperBeta0', COL1 ); 
 call symput('fuperBeta1', COL2 ); 
run; 
proc nlmixed data=finecoarseB XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine and Coarse logviruscopies 
comparison"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1.2 beta0=&fuperBeta0 
beta1=&fuperBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*Coarse; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





/*Effect of BMI as continuous*/ 
 
 proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= BMI/ dist=poisson ; 
  repeated subject = subject_id/printmle; 




set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('cfBeta1', COL2 ); 
 call symput('cfBeta0', COL1 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 





 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&cfBeta0 
beta1=&cfBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*BMI; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




   proc genmod data = coarsetotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= BMI/dist=poisson; 
  repeated subject =  subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ccBeta1', COL2 ); 
 call symput('ccBeta0', COL1 ); 
run; 
 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of BMI"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ccBeta0 
beta1=&ccBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j+ + beta1* BMI; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





  proc genmod data = nptotal ; 
  class  subject_id sampleid; 





  repeated subject =  subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ccBeta1', COL2 ); 
 call symput('ccBeta0', COL1 ); 
run; 
 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP swab Particles: Effect of BMI"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ccBeta0 
beta1=&ccBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j+ + beta1* BMI; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





/*BMI as catogorical*/ 
data finetotal; 
set finetotal; 
if BMI>25 then X1 = 1; else X1 = 0; 
 run;quit; 
proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= X1/ dist=poisson ; 
  repeated subject = subject_id/printmle; 




set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 





 call symput('cfBeta0', COL1 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles: Effect of BMI"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&cfBeta0 
beta1=&cfBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 






if BMI>25 then X1 = 1; else X1 = 0; 
 run;quit; 
   proc genmod data = coarsetotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= X1/dist=poisson; 
  repeated subject =  subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ccBeta1', COL2 ); 
 call symput('ccBeta0', COL1 ); 
run; 
 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of BMI"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ccBeta0 
beta1=&ccBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j+ + beta1* X1; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 











if BMI>25 then X1 = 1; else X1 = 0; 
 run;quit; 
  proc genmod data = nptotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= X1/dist=poisson; 
  repeated subject =  subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ccBeta1', COL2 ); 
 call symput('ccBeta0', COL1 ); 
run; 
 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP swab Particles:Effect of BMI "; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ccBeta0 
beta1=&ccBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j+ + beta1* X1; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 






 /*Within NP swab, study the effect of lower upper and systemic 
symptoms*/ 
 
 proc genmod data = nptotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= lower_sym upper_sym 
systemic_sym/dist=poisson; 
   repeated subject = subject_id/ printmle; 







set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fdpoBeta0', COL1 ); 
 call symput('fdpoBeta1', COL2 ); 
 call symput('fdpoBeta2', COL3 ); 
  call symput('fdpoBeta3', COL4 ); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: Effect of lower upper and 
systemic"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fdpoBeta0 
beta1=&fdpoBeta1 beta2=&fdpoBeta2 beta3=&fdpoBeta3; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*lower_sym + beta2*upper_sym + 
beta3*systemic_sym; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





/*Study the effect of gender, Male is 1*/ 
proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= sex/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ftBeta1', COL2 ); 
 call symput('ftBeta0', COL1 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 





 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ftBeta0 
beta1=&ftBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*sex; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




 proc genmod data = coarsetotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= sex/dist=poisson; 
  repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ctBeta1', COL2 ); 
 call symput('ctBeta0', COL1 ); 
run; 
 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: sex"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ctBeta0 
beta1=&ctBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*sex; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




 proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies=sex/dist=poisson; 





  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ntBeta1', COL2 ); 
 call symput('ntBeta0', COL1 ); 
run; 
 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: sex"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ntBeta0 
beta1=&ntBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*sex; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





/*Study the effect of smoking*/ 
proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= Smoker/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ftBeta1', COL2 ); 
 call symput('ftBeta0', COL1 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles: Smoker"; 






 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*Smoker; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




 proc genmod data = coarsetotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= Smoker/dist=poisson; 
  repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ctBeta1', COL2 ); 
 call symput('ctBeta0', COL1 ); 
run; 
 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Smoker"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ctBeta0 
beta1=&ctBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*Smoker; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




 proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies=Smoker/dist=poisson; 
repeated subject = subject_id/ printmle; 







set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ntBeta1', COL2 ); 
 call symput('ntBeta0', COL1 ); 
run; 
 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: Smoker"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ntBeta0 
beta1=&ntBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*Smoker; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





/*Study the effect of anitiviral medication taken within 24 hours*/ 
 
proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= anitviral_24h/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ftBeta1', COL2 ); 
 call symput('ftBeta0', COL1 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles: Antiviral medication"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ftBeta0 
beta1=&ftBeta1; 





 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*anitviral_24h; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




 proc genmod data = coarsetotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= anitviral_24h/dist=poisson; 
  repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ctBeta1', COL2 ); 
 call symput('ctBeta0', COL1 ); 
run; 
 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: anitviral_24h"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ctBeta0 
beta1=&ctBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*anitviral_24h; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




 proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies=anitviral_24h/dist=poisson; 
repeated subject = subject_id/ printmle; 







set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ntBeta1', COL2 ); 
 call symput('ntBeta0', COL1 ); 
run; 
 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: anitviral_24h"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ntBeta0 
beta1=&ntBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*anitviral_24h; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 






/*For fine model, take cough_number day post symptom and systemic 




   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 systemic_sym 
sex/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 









 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
  call symput('unfBeta5', COL6 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of cough_num dpo2 
dpo3 Systemic_sym SEX "; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4 
beta5=&unfBeta5; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*systemic_sym + beta5*sex; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 









   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
  proc genmod data = coarsetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 sex/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 





  call symput('unfBeta5', COL6 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of  cough_num 
dpo2 dpo3 SEX"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*sex; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





/*For NP model, take lower upper and systemic symptom score and 
gender*/ 
 
proc genmod data = nptotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= lower_sym upper_sym systemic_sym 
sex/dist=poisson; 
   repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fdpoBeta0', COL1 ); 
 call symput('fdpoBeta1', COL2 ); 
 call symput('fdpoBeta2', COL3 ); 
 call symput('fdpoBeta3', COL4 ); 
 call symput('fdpoBeta4', COL5 ); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: Effect of lower upper 
systemic sex"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fdpoBeta0 
beta1=&fdpoBeta1 beta2=&fdpoBeta2 beta3=&fdpoBeta3 beta4=&fdpoBeta4; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*lower_sym + beta2*upper_sym + 





 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 









   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 sex/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of cough_num dpo2 
dpo3 SEX "; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*sex; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 










/*For fine model, take cough_number day post onset,gender and 
interaction between gender and cough number*/ 
data finetotal; 
set finetotal; 
   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 sex 
sex*cough_number/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
 call symput('unfBeta5', COL6 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of cough_num dpo2 
dpo3 SEX SEX*COUGH"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4 
beta5=&unfBeta5; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*sex +beta5*sex*cough_number; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 








/*For fine model, take cough_number day post onset, gender,systemic 




   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 sex systemic_sym 
sex*cough_number/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
 call symput('unfBeta5', COL6 ); 
  call symput('unfBeta6', COL7 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of cough_num dpo2 
dpo3 SEX systemic SEX*COUGH"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4 
beta5=&unfBeta5 beta6=&unfBeta6; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*sex + beta5*systemic_sym + beta6*sex*cough_number; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 












   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 systemic_sym 
sex*cough_number/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
 call symput('unfBeta5', COL6 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of cough_num dpo2 
dpo3 systemic SEX*COUGH"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4 
beta5=&unfBeta5; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*systemic_sym + beta5*sex*cough_number; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 







/*For fine model, take cough_number, day post onset, gender, and 









   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 sex sex*X1 
sex*X2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
 call symput('unfBeta5', COL6 ); 
  call symput('unfBeta6', COL7 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of cough_num dpo2 
dpo3 SEX SEX*dpo2 sex*dpo3"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4 
beta5=&unfBeta5 beta6=&unfBeta6; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*sex +beta5*sex*X1 +beta6*sex*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





/*For fine model, take cough_number, day post onset, gender, 
interaction between gender and day post onset and interaction 








   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 sex*cough_number sex*X1 
sex*X2/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
 call symput('unfBeta5', COL6 ); 
  call symput('unfBeta6', COL7 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of cough_num dpo2 
dpo3 SEX*cough SEX*dpo2 sex*dpo3"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4 
beta5=&unfBeta5 beta6=&unfBeta6; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*sex*cough_number +beta5*sex*X1 +beta6*sex*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 







   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 





  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 sex*cough_number sex*X1 
sex*X2 sex /dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
 call symput('unfBeta5', COL6 ); 
  call symput('unfBeta6', COL7 ); 
    call symput('unfBeta7', COL8 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of cough_num dpo2 
dpo3 SEX*cough SEX*dpo2 sex*dpo3 sex"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4 
beta5=&unfBeta5 beta6=&unfBeta6 beta7=&unfBeta7; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*sex*cough_number +beta5*sex*X1 +beta6*sex*X2 + 
beta7*sex; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





/*For coarse model, take cough_number, day post onset, gender, and 




   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 





  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 sex 
sex*cough_number/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
 call symput('unfBeta5', COL6 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of cough_num 
dpo2 dpo3 SEX  SEX*COUGH"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4 
beta5=&unfBeta5; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*sex + beta5*sex*cough_number; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





/*For Coarse model, take cough_number, day post onset, gender, and 




   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
 proc genmod data = coarsetotal; 
  class  subject_id sampleid ; 






 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
 call symput('unfBeta5', COL6 ); 
  call symput('unfBeta6', COL7 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of cough_num 
dpo2 dpo3 SEX  SEX*dpo2 SEX*dpo3"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4 
beta5=&unfBeta5 beta6=&unfBeta6; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*sex + beta5*sex*X1 + beta6*sex*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





/*For fine model, take cough_number, day post onset, gender, and 





   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 
sex*cough_number/dist=poisson; 





  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of cough_num dpo2 
dpo3 SEX*cough"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*sex*cough_number; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 






 If body_temp GE 37.8 then fever = 1; else fever = 0; 
 run;quit; 
 
 proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= fever upper_sym fever*upper_sym 
/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 








 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of fever upper_sym 
fever*upper_sym"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*fever + beta2*upper_sym + 
beta3*fever*upper_sym; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 







 If body_temp GE 37.8 then fever = 1; else fever = 0; 
 run;quit; 
 
 proc genmod data = nptotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= fever upper_sym fever*upper_sym 
/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 






 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*fever + beta2*upper_sym + 
beta3*fever*upper_sym; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 





/* test for A/B if the day post onset play an effect*/ 
data fineAtotal; 
set finetotal; 





 if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
  
 proc genmod data = fineAtotal; 
  class  subject_id sampleid; 
  model logfinalcopies= X1 X2/dist=poisson; 
   repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fdpoBeta0', COL1 ); 
 call symput('fdpoBeta1', COL2 ); 
 call symput('fdpoBeta2', COL3 ); 
run; 
proc nlmixed data=fineAtotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles with flu A infection: 
Effect of day_post_onset"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fdpoBeta0 
beta1=&fdpoBeta1 beta2=&fdpoBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 





 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 












 if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
  
 proc genmod data = fineBtotal; 
  class  subject_id sampleid; 
  model logfinalcopies= X1 X2/dist=poisson; 
   repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fdpoBeta0', COL1 ); 
 call symput('fdpoBeta1', COL2 ); 
 call symput('fdpoBeta2', COL3 ); 
run; 
proc nlmixed data=fineBtotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles with flu B infection: 
Effect of day_post_onset"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fdpoBeta0 
beta1=&fdpoBeta1 beta2=&fdpoBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1+ beta2*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 


















 if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
  
 proc genmod data = coarseAtotal; 
  class  subject_id sampleid; 
  model logfinalcopies= X1 X2/dist=poisson; 
   repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fdpoBeta0', COL1 ); 
 call symput('fdpoBeta1', COL2 ); 
 call symput('fdpoBeta2', COL3 ); 
run; 
proc nlmixed data=coarseAtotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of coarse Particles with flu A infection: 
Effect of day_post_onset"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fdpoBeta0 
beta1=&fdpoBeta1 beta2=&fdpoBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1+ beta2*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 
















 if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
  
 proc genmod data = coarseBtotal; 
  class  subject_id sampleid; 
  model logfinalcopies= X1 X2/dist=poisson; 
   repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fdpoBeta0', COL1 ); 
 call symput('fdpoBeta1', COL2 ); 
 call symput('fdpoBeta2', COL3 ); 
run; 
proc nlmixed data=coarseBtotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of coarse Particles with flu B infection: 
Effect of day_post_onset"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fdpoBeta0 
beta1=&fdpoBeta1 beta2=&fdpoBeta2; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1+ beta2*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 









 if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 







 proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= X1 X2 X3/dist=poisson; 
   repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fdpoBeta0', COL1 ); 
 call symput('fdpoBeta1', COL2 ); 
 call symput('fdpoBeta2', COL3 ); 
 call symput('fdpoBeta3', COL4 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles : Effect of day_post_onset 
AND TYPE AB"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fdpoBeta0 
beta1=&fdpoBeta1 beta2=&fdpoBeta2 beta3=&fdpoBeta3; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1+ beta2*X2 + beta3*X3; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 







 if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
if typeAB='A' then X3=1; else X3=0; 
 run;quit; 
  
 proc genmod data = coarsetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= X1 X2 X3/dist=poisson; 
   repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 











 set Paramst; 
 call symput('fdpoBeta0', COL1 ); 
 call symput('fdpoBeta1', COL2 ); 
 call symput('fdpoBeta2', COL3 ); 
 call symput('fdpoBeta3', COL4 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles : Effect of 
day_post_onset AND TYPE AB"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fdpoBeta0 
beta1=&fdpoBeta1 beta2=&fdpoBeta2 beta3=&fdpoBeta3; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1+ beta2*X2 + beta3*X3; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 







 if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
if typeAB='A' then X3=1; else X3=0; 
 run;quit; 
  
 proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= X1 X2 X3 X3*X1 X3*X2/dist=poisson; 
   repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fdpoBeta0', COL1 ); 
 call symput('fdpoBeta1', COL2 ); 
 call symput('fdpoBeta2', COL3 ); 





 call symput('fdpoBeta4', COL5 ); 
  call symput('fdpoBeta5', COL6 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles : Effect of day_post_onset 
AND TYPE AB"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fdpoBeta0 
beta1=&fdpoBeta1 beta2=&fdpoBeta2 beta3=&fdpoBeta3 beta4=&fdpoBeta4 
beta5=&fdpoBeta5; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1+ beta2*X2 + beta3*X3 
+beta4*X3*X1 + beta5*X3*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 







 if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
if typeAB='A' then X3=1; else X3=0; 
 run;quit; 
  
 proc genmod data = coarseftotal; 
  class  subject_id sampleid; 
  model logfinalcopies= X1 X2 X3 X3*X1 X3*X2/dist=poisson; 
   repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fdpoBeta0', COL1 ); 
 call symput('fdpoBeta1', COL2 ); 
 call symput('fdpoBeta2', COL3 ); 
 call symput('fdpoBeta3', COL4 ); 
 call symput('fdpoBeta4', COL5 ); 
  call symput('fdpoBeta5', COL6 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles : Effect of 





 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fdpoBeta0 
beta1=&fdpoBeta1 beta2=&fdpoBeta2 beta3=&fdpoBeta3 beta4=&fdpoBeta4 
beta5=&fdpoBeta5; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*X1+ beta2*X2 + beta3*X3 
+beta4*X3*X1 + beta5*X3*X2; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 










   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 BMI/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of cough_num dpo2 
dpo3 BMI"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 





 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 







   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
  proc genmod data = coarsetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 BMI/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
  call symput('unfBeta5', COL6 ); 
run; 
proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: Effect of  cough_num 
dpo2 dpo3 BMI"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*BMI; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 












   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies= cough_number X1 X2 sex*cough_number 
BMI/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
 call symput('unfBeta5', COL6 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of cough_num dpo2 
dpo3 SEX*cough BMI"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4 
beta5=&unfBeta5; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*sex*cough_number +beta5*BMI; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 










/* Effect of body temperature as continuous for NP,Fine and coarse 
*/ 
 proc genmod data = finetotal; 
  class  subject_id sampleid; 
  model logfinalcopies= body_temp/dist=poisson; 
 repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ftBeta1', COL2 ); 
 call symput('ftBeta0', COL1 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Fine Particles: Effect of fever"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ftBeta0 
beta1=&ftBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*body_temp; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




 proc genmod data = coarsetotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= body_temp/dist=poisson; 
  repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ctBeta1', COL2 ); 







proc nlmixed data=coarsetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of Coarse Particles: body_temp as 
continuous"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ctBeta0 
beta1=&ctBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*body_temp; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 




 proc genmod data = nptotal; 
  class  subject_id sampleid; 
  model logfinalcopies=body_temp/dist=poisson; 
repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('ntBeta1', COL2 ); 
 call symput('ntBeta0', COL1 ); 
run; 
 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: body_temp as continuous"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&ntBeta0 
beta1=&ntBeta1; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*body_temp; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 









proc genmod data = nptotal ; 
  class  subject_id sampleid; 
  model logfinalcopies= lower_sym upper_sym systemic_sym 
age/dist=poisson; 
   repeated subject = subject_id/ printmle; 
  ods OUTPUT  parameterestimates=params; 
run; 
data Params; 
set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('fdpoBeta0', COL1 ); 
 call symput('fdpoBeta1', COL2 ); 
 call symput('fdpoBeta2', COL3 ); 
 call symput('fdpoBeta3', COL4 ); 
 call symput('fdpoBeta4', COL5 ); 
run; 
proc nlmixed data=nptotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of NP Particles: Effect of lower upper 
systemic age"; 
 parms sigma2_u= 1 sigma2_u1= 1 sigma2= 0.1 beta0=&fdpoBeta0 
beta1=&fdpoBeta1 beta2=&fdpoBeta2 beta3=&fdpoBeta3 beta4=&fdpoBeta4; 
 bounds sigma2_u sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j +b_1j + beta1*lower_sym + beta2*upper_sym + 
beta3*systemic_sym + beta4*age; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies-mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 







   if dpo=2 then X1=1;else X1=0; 
if dpo=3 then X2=1; else X2=0; 
 If typeAB='A' then fineA=1;else fineA=0; 
 if typeAB='B' then fineB=1;else fineB=0; 
 run;quit; 
 
  proc genmod data = finetotal; 
  class  subject_id sampleid ; 
  model logfinalcopies=  cough_number X1 X2 sex*cough_number BMI 
fineA*fluvac_cur fineB*fluvac_cur/dist=poisson; 
 repeated subject = subject_id/ printmle; 







set Params (keep=Parameter Estimate); 
run; 
 




 set Paramst; 
 call symput('unfBeta0', COL1 ); 
 call symput('unfBeta1', COL2 ); 
 call symput('unfBeta2', COL3 ); 
 call symput('unfBeta3', COL4 ); 
 call symput('unfBeta4', COL5 ); 
 call symput('unfBeta5', COL6 ); 
 call symput('unfBeta6', COL7 ); 
  call symput('unfBeta7', COL8 ); 
run; 
proc nlmixed data=finetotal XTOL=1E-12 method=GAUSS qpoints=100; 
Title "Tobit Regression of fine Particles: Effect of cough_num dpo2 
dpo3 SEX*cough BMI subtype*vaccination"; 
 parms sigma2_u= 1 sigma2_u1=1 sigma2= 1 beta0=&unfBeta0 
beta1=&unfBeta1 beta2=&unfBeta2 beta3=&unfBeta3 beta4=&unfBeta4 
beta5=&unfBeta5 beta6=&unfBeta6 beta7=&unfBeta7; 
 bounds sigma2_u  sigma2_u1 sigma2 >= 0; 
 pi = constant('pi'); 
 mu = beta0 + b_0j+ b_1j + beta1*cough_number + beta2*X1 + 
beta3*X2 + beta4*sex*cough_number +beta5*BMI + 
beta6*fineA*fluvac_cur + beta7*fineB*fluvac_cur; 
 if final_copies ne . then ll = (1 / (sqrt(2*pi*sigma2))) * 
exp( -(logfinalcopies - mu)**2 / (2*sigma2) ); 
 if final_copies = .  then ll = probnorm( (logfinalcopies - mu) 
/ sqrt(sigma2) ); 
 L=log(ll); 
 model logfinalcopies~ general(L); 
 random b_0j ~ normal(0,sigma2_u) subject=subject_id; 
 random b_1j~ normal(0, sigma2_u1) 
subject=sampleid(subject_id); 
 run; 
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𝐷𝐷�1 = 𝜅𝜅𝑤𝑤,1 𝐼𝐼 −
1
𝜈𝜈1
𝐷𝐷�1   ,
𝑑𝑑
𝑑𝑑𝑑𝑑
𝐷𝐷�2 = 𝜅𝜅𝑤𝑤,2 𝐼𝐼 −
1
𝜈𝜈2




?̂?𝑆𝑟𝑟  = 𝑆𝑆𝑟𝑟/𝑁𝑁         A.(1e) 
 
?̂?𝑆𝑛𝑛𝑟𝑟  = 𝑆𝑆𝑛𝑛𝑟𝑟/𝑁𝑁         A.(1f) 
 
𝐼𝐼  = 𝐼𝐼/𝑁𝑁         A.(1g) 
 
𝐷𝐷�  = 𝐷𝐷/𝑁𝑁         A.(1h) 
 
The boundary conditions are: 
 






?̂?𝑆𝑛𝑛𝑟𝑟(0)  = ?̂?𝑆𝑛𝑛𝑟𝑟,0 =  𝑆𝑆𝑛𝑛𝑟𝑟,0/𝑁𝑁       A.(1j) 
 
𝐼𝐼(0) = 𝐼𝐼0  = 𝐼𝐼0/𝑁𝑁        A. (1k) 
 
𝐷𝐷� (0) = 0             A.(1l) 












𝐼𝐼 = − 𝑑𝑑
𝑑𝑑𝑑𝑑




𝐷𝐷�1 = 𝜅𝜅𝑤𝑤,1 𝐼𝐼 −
1
𝜈𝜈1
𝐷𝐷�1   ,
𝑑𝑑
𝑑𝑑𝑑𝑑
𝐷𝐷�2 = 𝜅𝜅𝑤𝑤,2 𝐼𝐼 −
1
𝜈𝜈2
𝐷𝐷�2  ,⋯ ,
𝑑𝑑
𝑑𝑑𝑑𝑑
𝐷𝐷�𝑗𝑗 = 𝜅𝜅𝑤𝑤,𝑗𝑗 𝐼𝐼 −
1
𝜈𝜈𝑗𝑗




𝛽𝛽�𝑟𝑟,𝑗𝑗  =  𝑇𝑇𝑖𝑖𝑛𝑛,𝑗𝑗𝑐𝑐
𝐵𝐵
𝑉𝑉𝑐𝑐𝑐𝑐
𝜏𝜏𝜏𝜏𝜏𝜏𝑖𝑖𝑁𝑁𝑝𝑝,𝑗𝑗           B. (2e) 
 
𝛽𝛽�𝑛𝑛𝑟𝑟,𝑗𝑗  =  𝑐𝑐
𝐵𝐵
𝑉𝑉𝑐𝑐𝑐𝑐
𝜏𝜏𝜏𝜏𝜏𝜏𝑗𝑗𝑁𝑁𝑝𝑝,𝑗𝑗           B. (2f) 
 






𝑅𝑅−1𝑗𝑗 = (1 + 𝑐𝑐𝜏𝜏)
𝐵𝐵
𝑉𝑉𝑐𝑐𝑐𝑐
𝜏𝜏𝑗𝑗 + 𝜇𝜇𝑑𝑑 + 𝜃𝜃𝑗𝑗          B. (2h) 
 
We consider boundary conditions analogous to those for the monodisperse case: 
 
?̂?𝑆𝑟𝑟(0) =  ?̂?𝑆𝑟𝑟0               B. (2i) 
 
?̂?𝑆𝑛𝑛𝑟𝑟(0)  = ?̂?𝑆𝑛𝑛𝑟𝑟,0             B. (2j) 
 
𝐼𝐼(0) = 𝐼𝐼0                 B. (2k) 
 








Table D1. Deposition fraction in the respiratory tract of different inhaled particle sizes  
Particle size 
(µm) 
Deposition fraction of inhaled particles in the respiratory 
tract 
Adult Children 
0.3 0.11 0.11 
0.5 0.14 0.14 
0.7 0.26 0.32 
2.0 0.66 0.86 
2.5 0.71 0.78 









Smaldone et al. (2015) performed an in vitro study to determine the respiratory 
source control using RPDs. The results depend on the room type, the RPD type and 
whether the subject is coughing or breathing. The values can range from 2 to 4 for 
breathing and 5 to 17 for coughing. Since it is likely that a person spends their time 
breathing rather than coughing over a 4 to 8 hours’ period, hence we assume average 
values that hold for breathing conditions. We also assume that for RPDs the 
protection factor is not a strong function of the brand used or fits. We arbitrarily 
assume a slightly lower value for unfitted respirators comparing with fitted 
respirators.  
Regarding the respiratory receiver control using RPDs, with fitted N95, the 
results from bench top and subject experiments are mixed. While the former suggests 
no dependency on size, the later demonstrates at least some dependency. For fitted 
N95, we combine the findings and assume a size specific risk reduction: we assume a 
lower PF below 1 micron and then assume a relatively higher PF at larger values but 
then that does not increase with size.  For the unfitted N95, Brosseau et al, 2010 has 
demonstrated that without fit-testing, at least a PF of 2 would be expected for two 
brands of N95s. The low filtration surgical mask PF was determined by Guha et al. 
(2016) and, the lab work demonstrated the low filtration can make the PF close to 1.1 
which is the worst case. The high filtration surgical masks are likely to provide PF 
close to 7 as tested in Brosseau et al. (2008). the article does not provide any size 
dependency of leakage but the filtration is expected to strongly decay with increasing 
size. To be consistent with N95 data, we assume the PF doubles at size greater than or 





2 and 7 respectively for low and high filtration pediatric masks and are independent 
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